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Introduction
Regular participation in physical activity (PA) is an important component of
health and quality of life for people of all ages.

In general, individuals who are

physically active live longer, healthier lives than those who are less physically active due
to the numerous health benefits associated with PA (Table 1) (1-4). Therefore, increasing
PA participation among those who are sedentary and maintaining PA participation among
those who are already active is a major goal of researchers, health/fitness and exercise
professionals, and health care providers.
Table 1. The Benefits of Habitual Physical Activity (3, 4)
•

Reduces the risk of pre-mature all-cause mortality.

•

Reduces total body fat and, therefore, prevents and eliminates overweight and
obesity.

•

Reduces the risk of developing chronic diseases such as cardiovascular and
coronary heart disease, several types of cancer, type 2 diabetes mellitus, and
osteoporosis.

•

Reduces and can even eliminate the presence of risk factors for chronic disease,
such as high blood pressure and cholesterol.

•

Increases aerobic capacity, muscle strength, and endurance.

•

Increases an individual’s ability to engage in activities of daily living, known as
functional capacity.

•

Decreases anxiety and depression.

•

Reduces an individual’s risk of injury.

•

Improves cognitive function.
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In 2008, the United States Department of Health and Human Services (USDHHS)
published the Physical Activity Guidelines for Americans (3). This publication aims to
increase participation in PA by outlining the minimum PA recommendations necessary to
maintain a healthy lifestyle (3). These recommendations follow the Frequency, Intensity,
Time, and Type (FITT) principle of exercise prescription.
The intensity of different physical activities can be quantified using metabolic
equivalents (METs) (14). METs express the intensity of an activity in comparison to
resting energy expenditure, with one MET equal to the rate of energy expenditure at rest
(3.5 mL of oxygen/kg/min or 1 kcal/kg/hr for an average adult). The intensity level of a
given activity can be described simply as a multiple of 1 MET (14). Using METs, PA
can be grouped or classified using the following classifications: light (< 3 METs),
moderate (3-<6 METs), and vigorous (≥6 METs) intensity PA (14).
In the 2008 USDHHS PA guidelines, healthy adults age 18-64 yr are
recommended to participate in at least 150 minutes (2 hours and 30 minutes) of moderate
or 75 minutes (1 hour and 15 minutes) of vigorous intensity aerobic PA each week, or an
equivalent combination of the two (3) (Table 2). Examples of moderate intensity PA
include walking briskly, water aerobics, general gardening, bicycling (slower than 10
miles per hour), and ballroom dancing (3). Similarly, examples of vigorous intensity PA
include speed walking, jogging, running, bicycling (faster than 10 miles per hour), and
jumping rope (3).
For more extensive health benefits, such as losing and keeping off weight, the
USDHHS PA guidelines recommend healthy adults participate in at least 300 minutes (5
hours) of moderate or at least 150 minutes of vigorous intensity aerobic PA each week
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(3). The recommended aerobic PA should be performed in bouts of at least 10 minutes
and, preferably, should be spread throughout the week (3).
In addition to aerobic PA, healthy adults are also encouraged to participate in
activities designed to increase and maintain muscular strength and endurance. These
activities should involve all the major muscle groups and should be performed on two or
more days of the week (3).
Table 2. United States Department of Health and Human Services 2008 Minimum
Aerobic Physical Activity Recommendations for Adults 18-64 yr (3)
Frequency

3- ≥ 5 d/wk

Intensity

Moderate and/or Vigorous

Time

Type

20-60 min/d to total 150 min moderate, or
75 min vigorous, or combination; continuous or
accumulated
Aerobic
Resistance 2-3 d/wk
Flexibility 2-3 d/wk

The positive relationship between participation in PA and health is well known.
Physical activity, or a predominantly active lifestyle, is associated with a reduced risk for
developing several chronic diseases and health conditions such as cardiovascular disease,
type 2 diabetes mellitus, hypertension, and several forms of cancer including breast and
colon cancer. Additionally, PA results in a reduced risk for increased body weight, thus
preventing overweight and obesity (32, 42).
Despite efforts by the USDHHS to increase participation in PA, the number of
adults and youth in the United States who are active on a regular basis remains low. Only
3

35% of American adults over the age of 18 yr meet the minimum PA recommendations
set forth by the USDHHS (3, 5).
Along with low rates of PA, the number of people in the United States suffering
from chronic diseases remains high. According to the Centers for Disease Control and
Prevention, 133 million American adults suffered from at least one chronic disease in
2005 (44).

This translates to almost 1 out of every 2 American adults (44).

The

American Heart Association estimates 36.3% of adults in the United States suffer from
cardiovascular disease, 33.3% have hypertension, and 9.35% are diagnosed with type 2
diabetes mellitus (7). Further, an estimated 60% of adults in the United States over the
age of 20 yr meet the criteria for overweight and obesity (defined as a BMI ≥ 25 kg/m2)
(6, 8). Finally, cardiovascular disease, type 2 diabetes mellitus, and several forms of
cancer constitute about 70% of all deaths in the United States (6).
These high rates of chronic disease pose numerous problems. First, chronic
disease creates an enormous financial burden to society. In 2005, an estimated 75% of
the United States’ $2 trillion medical care budget was devoted to the direct cost of caring
for patients with chronic diseases (6). The presence of a chronic disease may also result
in a significant loss of wages for the individual with the disease due to time spent away
from work (6). In addition to the financial burden, chronic disease can result in a lower
quality of life, a loss of independence, and decreased longevity (6). Finally, chronic
disease can increase an individual’s risk for developing mood disorders such as anxiety
and depression (9).
Since participation in PA is known to reduce the risk for developing chronic
diseases, researchers are currently examining the efficacy of different policies, strategies
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and interventions aimed at increasing the number of people in the United States who
participate in PA on a regular basis. However, in order to know whether or not a
particular intervention is effective, reliable and valid tools for measuring and assessing
PA are necessary.
Self-Report PA Questionnaires: Habitual participation in PA can be measured and
assessed through a variety of methods including accelerometers, cardiorespiratory fitness
(CRF), daily PA logs, and direct observation (32). Self-report PA questionnaires are
currently one of the most practical and widely used methods for assessing PA (10).
These questionnaires typically ask respondents to recall participation in certain activities
over a specific period of time, and are often used in large epidemiological studies
examining the relationship between PA and health outcomes (10, 11).
As is the case with other methods of assessing PA, there are both benefits and
limitations associated with using PA questionnaires (Table 3).

For instance, PA

questionnaires are inexpensive, quick, and relatively easy to administer to large groups of
people (1, 2, 12, 13). However, using PA questionnaires to assess participation in PA can
result in a greater misclassification of PA habits than objective PA measures due to recall
and social desirability biases (12, 15). Additionally, PA questionnaires that are currently
available

often

differ

in

terms

of

mode

of

administration

(i.e.,

administered/interview), complexity, length, and difficulty of scoring (28).

selfThese

differences can have an impact on the efficacy of the questionnaire at measuring and
assessing PA. Therefore, before a questionnaire is used to assess PA, it is imperative that
it be validated against a criterion measure.

5

Table 3. The Benefits and Limitations of Self-Report Physical Activity
Questionnaires (15)

•
•
•

•

Benefits
Low Cost.
Easy to administer to large
groups of people.
Easily adapted to fit the needs of
a particular population or
research question.
Possible to assess all of the
dimensions of PA so behavior
patterns can be examined.

•
•

•

•

Limitations
Over reporting of PA often occurs due
to social desirability response bias.
Recalling PA is a highly complex
cognitive task, and children and older
adults may have memory or recall skill
limitations.
Researcher and respondent must share
an understanding of ambiguous terms
such as “physical activity,” “moderate
intensity,” “vigorous intensity,” or
“leisure time.”
Accuracy of results depends on the
respondent’s ability to follow directions.

The Paffenbarger Physical Activity Questionnaire (PPAQ) is a short, selfadministered questionnaire designed to measure participation in leisure time PA among
young and older adults (29). The current form of the PPAQ consists of eight questions.
The first four questions ask respondents to report the number of city blocks they walk and
flights of stairs they climb on a typical day, as well as to list the frequency and duration
of any sports or recreational activities they participated in over the past year (30). From
the answers to these questions, a physical activity index (PAI) can be computed,
providing an estimate of energy expenditure (30).
Question six (Q6) of the PPAQ asks respondents to report whether or not they
engage in regular PA long enough to work up a sweat, get their heart thumping or get out
of breath at least once a week. If the answer is yes, respondents are asked to report the
frequency and the type of activity. Both the PAI and the PPAQ Q6 have been validated
against CRF, accelerometers, daily PA logs, and various health outcomes, i.e. body mass
index (BMI) and high-density lipoprotein (HDL) cholesterol and are believed to be good
6

measures of participation in moderate and vigorous intensity PA (13, 31, 43).
Question eight (Q8) of the PPAQ asks respondents to report the number of hours
they spend on a typical day during the week and weekend sleeping, sitting, and
participating in light, moderate, and vigorous intensity PA. Q8 is a useful component of
the PPAQ because it assesses participation in sedentary and light activities as well as
moderate and vigorous intensity activities, thus providing a more complete estimate of
PA than the other components of the PPAQ can on their own.
Several studies have examined the validity of the PPAQ Q8 (32, 43). However,
these studies used subject populations consisting of post-menopausal women and
individuals of low socioeconomic status (32, 43), so the results may not be generalizable
to other populations. Additionally, to the best of the author’s knowledge, no study has
examined the reliability of Q8.

Therefore, a study investigating the validity and

reliability of the PPAQ Q8 using a subject population of healthy men and women across
the lifespan, regardless of socioeconomic status, is necessary.
Thus, the purpose of this study was to examine the criterion validity as well as the
test-retest reliability of the PPAQ Q8. Criterion validity of a PA questionnaire is the
degree to which PA measured by responses on the questionnaire match PA measured by a
gold standard or a well accepted method of assessing PA (i.e. an accelerometer). There
are two main types of criterion validity: concurrent and predictive.

Concurrent validity

is the degree to which PA measured by a questionnaire matches PA measured by a gold
standard when the questionnaire and gold standard are administered at the same point in
time. Predictive validity is the degree to which PA measured by a questionnaire matches
PA measured by a gold standard when the questionnaire and gold standard are
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administered at different time points. Finally, test-retest reliability of a PA questionnaire
refers to the degree to which a subject’s responses on the questionnaire match the same
subject’s responses on the questionnaire after a certain period of time. In other words,
reliability refers to the stability of responses on the questionnaire over a certain period of
time.
This current study utilizes data obtained from a larger National Institutes of
Health (NIH) funded (1R01HL081893-01A2) study entitled, “The Effects of Statins on
Muscle Performance” (STOMP).

Therefore, this study is a sub-study of STOMP.

STOMP examined the incidence rate of statin-induced muscle symptoms defined as
myalgia, as well as the effects of statins on skeletal muscle strength, endurance and
aerobic exercise performance in healthy men and women over 20 yr taking either 80 mg
of Atorvastatin (Lipitor) or placebo daily for six months.
In this sub-study of STOMP, objectively measured PA from an accelerometer was
used to examine the concurrent validity of the PPAQ Q8. Additionally, the predictive
validity of the PPAQ Q8 was examined by comparing subject responses on Q8 with CRF,
measured by VO2max, and various health outcomes known to be associated with
participation in PA including blood pressure (BP), mean arterial pressure (MAP),
triglycerides (TG), total cholesterol (TC), HDL cholesterol, low-density lipoprotein
(LDL) cholesterol, resting heart rate (HR), BMI, and waist circumference (WC). Finally,
the test-retest reliability of the PPAQ Q8 was examined by comparing subject responses
on the PPAQ Q8 at baseline with subject responses at three and six months following
baseline.
Specific Aims and Hypotheses: The purpose of this sub-study of STOMP was to
8

examine the efficacy of the PPAQ Q8 as a tool for assessing PA by investigating its
criterion and predictive validity as well as its test-retest reliability.
Specific Aim 1: To assess the concurrent validity of the PPAQ Q8 by examining
the relationships among average self-reported hr/d spent in each PA intensity category on
Q8 and measurements from an Actical accelerometer, including average daily steps (d-1),
activity counts (d-1), energy expenditure (kcal/d), and average time (min/d) spent in each
PA intensity category.
Hypothesis 1: Average self-reported hr/d spent participating in moderate and
vigorous intensity PA on the PPAQ Q8 will be positively correlated with average daily
steps (d-1), activity counts (d-1), and energy expenditure (kcal/d) measured with the
Actical accelerometer.

Additionally, average self-reported hr/d spent in each PA

intensity category on the PPAQ Q8 will be positively correlated with average min/d spent
in each PA intensity category measured with an Actical accelerometer.
Specific Aim 2: To determine the predictive validity of the PPAQ Q8 by
examining the relationships among average self-reported hr/d spent in each PA intensity
category on the PPAQ Q8 and CRF, measured by VO2max.
Hypothesis 2: Average self-reported hr/d spent in vigorous intensity PA on the
PPAQ Q8 will be positively correlated with VO2max.
Specific Aim 3: To further determine the predictive validity of the PPAQ Q8 by
examining the relationships among average self-reported hr/d spent in each PA intensity
category on the PPAQ Q8 and several health outcomes including BP, MAP, TG, TC,
HDL and LDL cholesterol, resting HR, BMI, and WC.
Hypothesis 3: Average self-reported hr/d spent engaging in vigorous and
9

moderate intensity PA on the PPAQ Q8 will show weak, negative associations with BP,
MAP, TG, TC, LDL cholesterol, resting HR, BMI, and WC and weak, positive
associations with HDL cholesterol.
Specific Aim 4:

To examine the test-retest reliability of the PPAQ Q8 by

comparing average self-reported hr/d spent in each PA intensity category on the PPAQ
Q8 at baseline with average self-reported hr/d spent in each PA intensity category on the
PPAQ Q8 three and six months from baseline.
Hypothesis 4: Average self-reported hr/d spent in each PA intensity category on
the PPAQ Q8 at baseline will not be significantly different from average self-reported
hr/d spent in each PA intensity category reported by the same subjects on the PPAQ Q8
three and six months from baseline.
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Literature Review
Validation of Physical Activity Questionnaires: The validity and reliability of a PA
questionnaire must be examined prior to it being used to measure and assess participation
in PA. To do this, researchers commonly use accelerometers, CRF, and health outcomes
known to be associated with participation in PA.
Accelerometers: Researchers often use data from accelerometers as a criterion
measure to validate PA questionnaires. Accelerometers are objective PA monitors that
allow researchers to examine the frequency, intensity, and duration of PA performed by
individuals (21). Considerable research has been conducted to examine the ability of
accelerometers to assess PA.

Overall, accelerometers have been shown to provide

accurate estimates of PA under laboratory conditions. Additionally, accelerometers are
small in size, generally well tolerated by participants, and have long-term data storage
capabilities (24). As a result, the use of accelerometers in epidemiological studies has
become very common over the past several years (22, 23).
The Actical is a fairly new PA monitor currently on the market. It uses a single
omni-directional accelerometer to detect motion in multiple directions. However, it is
most sensitive within the vertical plane (25). The Actical is capable of detecting low
frequency G-forces produced during human movement. Each time a force is detected,
the Actical produces a voltage signal that varies in magnitude depending on the intensity
of the detected force. This voltage signal is then amplified and digitized. The digitized
values are then summed over a specified period of time, known as an epoch, between 15
sec and 1 min (24, 25). Since the data stored by the Actical are proportional to the
magnitude and duration of the motions sensed by the accelerometer, they correspond to
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the changes in energy expenditure that occurs during PA (24, 25).
Heil (2006) investigated the efficacy of the Actical accelerometer as a means of
assessing PA (24). To do this, Heil (2006) fit 24 children and 24 adults with three
Actical accelerometers and a small backpack containing a portable metabolic
measurement system. Participants wore one Actical on their wrist, another on their ankle,
and one on a belt around their hip. Volunteers then completed various activities in the
lab including resting, sitting activities, household cleaning activities, walking, and
jogging. The researchers used VO2 measured by the portable metabolic measurement
system to compute activity energy expenditure (AEE) (24).
Regression analysis was then used to create one regression (1R) and two
regression (2R) models for predicting AEE using the Actical data output from each of the
three accelerometers. The resulting 1R and 2R models were then incorporated into
algorithms for computing AEE and time values corresponding to sedentary and light
(AEESL, kcal; TSL, min), moderate (AEEMOD, kcal; TMOD, min), and vigorous (AEEVIG,
min kcal; TVIG) intensity PA. The AEE and time variables were computed based on
minimum bout durations of 1, 3 and 5 min. The regression equations for each Actical
location were statistically significant for adults (R2=0.14-0.85, p<0.008) (24).
AEE derived from measures of VO2 were then compared to the predicted values
resulting from the 1R and 2R models.

For adults, the predicted AEE values were not

significantly different from the actual AEE values derived from VO2 for all of the 1R
algorithms and 2R algorithm for the hip-worn Actical (24). Mean values for AEEVIG
from the ankle (M=5.2 for the 1 min, M=1.0 for the 3 min, and M=1.0 for the 5 min
minimum bout duration, p<0.01) and wrist (M=2.9 for the 1 min, M=2.7 for the 3 min,
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and M=2.2 for the 5 min minimum bout duration, p<0.01) 2R algorithms were
significantly lower than the actual mean AEE values (M=43.9 for the 1 min, M=40.9 for
the 3 min, and M=28.4 for the 5 min minimum bout) (24).
Additionally, Heil computed the mean and standard deviation of the differences
between the predicted values of AEE and the actual AEE values.

The positive or

negative mean differences represented a tendency of the algorithm to under or
overestimate AEE. For adults, the 1R algorithms slightly overestimated most variables
(residuals of +4.2 to +15.7 kcal for AEESL, AEEmod, and AEETOT). In contrast, the 2R
algorithms for adults were less likely to overestimate AEE (residuals of -0.7 to +7.1kcal)
(24). As a result of these findings, Heil concluded the Actical accelerometer is a fairly
accurate tool for assessing AEE and, therefore, adult PA when worn on the ankle, wrist,
or hip (24).
Similarly, Eslinger et al. (2007) examined the validity of the step-count function
of the Actical accelerometer by comparing it to two criterion measures. First, eight
Actical accelerometers were activated and mounted to the surface of a shaker table. The
shaker table was then set to oscillate at six different intensities.

The shaker table

oscillations per minute for each intensity condition were compared to the number of steps
measured by the Actical to assess the ability of the Actical to record steps during each
intensity condition. Second, 38 volunteers age 9-59 yr were given eight Actical and eight
ActiGraph accelerometers to wear. After a warm up, the volunteers completed three 6
min exercise bouts on a treadmill: a slow walk (50 m⋅min-1), a normal walk (83 m⋅min-1),
and a run (133 m⋅min-1). A trained observer visually counted the steps taken by the
volunteer during minutes 2 and 4 of each exercise bout using a handheld tally counter
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(23).
The correlation between the number of steps detected by the Actical
accelerometer and the number of shaker table oscillations per minute during each
intensity condition was perfect (r = 1.0). Additionally, comparing the number of visually
counted steps with the number of steps detected by each accelerometer resulted in near
perfect agreement during the normal walk and the run conditions (r = 0.99 for both the
Actical and the ActiGraph accelerometers). However, agreement between the number of
visually counted steps and the number of steps detected by each accelerometer during the
slow walk was lower (r = 0.73 and 0.52 for the Actical and ActiGraph accelerometers,
respectively) (23). These results suggest both the Actical and ActiGraph accelerometers
underestimate the number of steps taken during slow walking, but are capable of
accurately measuring steps during normal walking and running (23).
The Actical accelerometer has been used in studies examining the validity of PA
questionnaires. For instance, Wolin et al. (2008) examined the validity of the short
version of the IPAQ in 142 African Americans age 24 to 70 yr. Subjects completed the
short version of the IPAQ, which asks respondents to report time spent over the past 7
days participating in walking, moderate, and vigorous intensity PA across leisure time,
work, domestic activities, and transportation.

For scoring, the following MET values

were used: light = 3.3 METs, moderate = 4.0 METs, and vigorous = 8.0 METs. Subjects
were considered to have met the minimum PA recommendations if they reported
participating in at least 150 min/week of walking, moderate, or vigorous intensity PA.
After completing the IPAQ, subjects wore an Actical accelerometer on their hip
for 6 consecutive days.

The raw activity data from the Actical accelerometer was
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converted to minute-by-minute AEE using the 2R algorithm for the Actical worn on the
hip. Activity counts and time spent within light, moderate, and vigorous intensity PA
were averaged across the total time each subject wore the accelerometer. Finally, the
AEE data were evaluated separately for two minimum bout lengths: 1 min and 10 min
(25).
When using the 1 min bout definition, moderate agreement between the IPAQ and
accelerometer determined activity counts was observed (r=0.36, p<0.001).

This

agreement was higher among men (r=0.58, p<0.001) and lower among women (r=0.21,
p<0.05).

Using the 10 min bout definition, the correlation between the IPAQ and

accelerometer measured activity counts was fair (r=0.26, p<0.002) for the whole sample,
moderate for men (r=0.48, p<0.003), and poor among women (r=0.07, p=0.48) (25).
The results of these studies suggest the Actical accelerometer is capable of
accurately measuring PA levels. Therefore, the Actical accelerometer can be used as a
criterion measure to assess the ability of a PA questionnaire to accurately estimate PA.
Cardiorespiratory Fitness: CRF refers to the ability of the circulatory and
respiratory systems to deliver oxygen to skeletal muscles during exercise, as well as the
ability of the muscles to absorb and use the oxygen to produce energy via cellular
respiration (4). As a result, CRF is related to the ability to perform moderate to high
intensity PA for prolonged periods of time (4). The gold standard measure of CRF is
maximal oxygen uptake (VO2max). Typically, VO2max is determined using indirect
calorimetry on a treadmill or bicycle ergometer (16, 17).
VO2 max is often used to validate PA questionnaires in addition to accelerometers
(18). For instance, Aadahl et al. (2006) investigated the validity of a new self-report PA
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questionnaire designed to measure PA on an average weekday. In this study, 102 healthy
men and women age 35-65 yr described their habitual PA on a typical weekday by
reporting the number of hours they spend participating in activities classified into nine
different intensity levels. The intensity levels ranged from sleeping (0.9 METS) to
vigorous PA (≥ 6.0 METS).

From the subject responses, a 24-hr MET score was

calculated. Subjects also rated their own physical fitness level as excellent, very good,
good, fair, or poor. VO2max was obtained from a standardized graded bicycle ergometer
test with increasing workload until exhaustion (12).
The total amount of PA reported by subjects was not significantly associated with
VO2max (r2=0.69, p=0.098).

However, there was a strong, significant association

between the amount of daily vigorous intensity PA and VO2max (r2=0.76, p=0.0001).
Additionally, a significant trend across the self-reported physical fitness groups of
excellent/very good, good, and fair/poor in relation to VO2max was observed (P for trend
<0.001) (12).
Richardson et al. (2001) investigated the validity of the Stanford 7-Day Recall (7DR) by comparing self-reported PA measured by the 7-DR with PA records, Caltrac
accelerometer readings, VO2max, and percent body fat. Test-retest reliability was
evaluated by comparing PA assessed by the 7-DR during two separate occasions. In this
study, 28 healthy men and 50 healthy women age 21-59 yr completed the 7-DR during
visits 10 and 11 of the National Heart, Lung and Blood Institute funded Survey of
Activity, Fitness and Exercise (SAFE) study. These two study visits were separated by
approximately 26 days (19).
The 7-DR asks subjects to report the number of hours they spent sleeping and
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engaging in moderate (3.0-5.0 METs), hard (5.1-6.9 METs), and very hard (≥7 METs)
PA during the previous seven days. The time subjects reported sleeping and engaging in
moderate, hard, and very hard PA was subtracted from 24 hrs to determine time spent
engaging in light activity (1.0-2.9 METs). For scoring, the following MET levels were
assigned to each PA category: sleep = 1 MET, light = 1.5 METs; moderate = 4 METs;
hard = 6 METs; and very hard = 10 METs. Results were reported as the product of the
MET level and the duration of activity in minutes (MET-minutes ⋅ day-1) (19). For 48 hrs
prior to SAFE study visits 10 and 11, subjects wore a Caltrac accelerometer and recorded
the PA they performed during this time period in a PA log. VO2max was measured using
a maximal graded treadmill test and percent body fat was determined by hydrostatic
weighing (19).
For men, total (r=0.49, p<0.05 at visit 10 and r=0.54, p<0.01 at visit 11) and very
hard (r=0.48, p<0.05 at visit 10 and r=0.62, p<0.01 at visit 11) PA measured by the 7-DR
during visits 10 and 11 were significantly correlated with VO2max. For women, the
correlations between total (r=0.14, p>0.05 at visit 10 and r=0.47, p<0.01 at visit 11) and
very hard (r=0.24, p>0.05 at visit 10 and r=0.42, p<0.01 at visit 11) PA measured by the
7-DR and VO2max were weaker and less consistent (19).
Kurtze et al. (2008) examined the validity of the short version of the IPAQ by
comparing PA measured by the IPAQ to VO2max and PA assessed by the ActiReg
activity monitor. In this study, 108 Norwegian men age 20-39 yr were randomly selected
from the Nord-Trøndelag Health Study (HUNT) to participate. VO2max was measured
for each subject in this study using a maximal graded treadmill test. Each subject then
wore an ActiReg activity monitor for seven consecutive days. Following this, volunteers

17

completed the IPAQ, which consisted of seven questions pertaining to the PA they
participated in during the previous seven days. These questions asked subjects to report
the number of days, hours and minutes they spent engaging in vigorous intensity PA,
moderate intensity PA, walking, and sitting during the previous week (20).
For scoring purposes, the following MET values were assigned to each activity
category: vigorous intensity PA = 8 METs, moderate intensity PA = 4 METs, and
walking = 3.3 METs. A total MET value for each activity category was calculated by
multiplying the time spent in each category by the category’s assigned MET value.
Additionally, a total was calculated for each intensity category by computing an index of
days, hours and minutes. Each subject completed the IPAQ a second time seven days
following the first administration of the questionnaire. PA assessed by the IPAQ during
the first administration of the questionnaire was compared to PA assessed by the second
administration to determine test-retest reliability of the IPAQ (20).
Subjects in this study who reported participating in the highest amount of
vigorous intensity PA over the previous seven days (4-6 hrs) also had the highest mean
VO2max (49.2 ml⋅kg-1⋅min-1).

VO2max also showed moderately strong, significant

correlations with total vigorous intensity PA, hours per week spent participating in
vigorous intensity PA, and number of days per week subjects reported participating in
vigorous intensity PA (r = 0.41, 0.40, and 0.36 respectively, p<0.01). Moderate intensity
PA, walking and sitting were not significantly correlated with VO2max (20).
The results of these studies suggest VO2max is associated with the amount of time
spent engaging in vigorous intensity PA. Therefore, VO2max can be used to assess the
ability of a PA questionnaire to accurately measure time spent in vigorous intensity PA.
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However, since CRF is influenced by genetics, VO2max cannot be the only method used
to validate a PA questionnaire.
Health Outcomes: In addition to accelerometers and VO2max, researchers often
use health outcomes associated with participation in PA to validate PA questionnaires.
For instance, Bowles et al. (2004) examined the validity of self-reported historical
walking, running, and jogging activity by comparing subject responses to anthropometric
measurements as well as CRF, BP, and serum lipids. In this study, 4,100 men 18-80 yr
and 963 women 18-75 yr underwent a medical examination at least once between the
years 1976 and 1985. During the medical examination, height, weight, BP, cholesterol,
and TG concentrations were measured. In addition, CRF was measured during the
examination by performance on a maximal treadmill test using a modified Balke protocol
(26).
In 1986, each study participant completed a survey designed to assess the amount
of walking, running, or jogging they completed each year during the previous decade.
Each participant was classified as sufficiently or insufficiently physically active based on
his or her responses on the survey. Men classified as sufficiently physically active had
significantly lower TG levels (mean difference = 28.38, p = 0.001) and BMI (mean
difference = 1.35, p <0.001) and higher treadmill times (mean difference = -4.96,
p<0.001) than men classified as insufficiently physically active. Women classified as
sufficiently physically active had significantly lower BMI (mean difference 0.80,
p<0.001) and higher treadmill times than women classified as insufficiently physically
active (mean difference = -4.63, p<0.001) (26).
Similarly, Graff-Iversen et al. (2007) examined the validity of the long version of
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the IPAQ. In this study, 1068 men and 1372 women 31-67 yr living in the Oslo region of
Norway completed the IPAQ. Investigators measured and recorded anthropometric and
biological characteristics of each subject. Such characteristics included height, weight,
WC, hip circumference, resting BP, HR, and serum cholesterol, glucose and TG. The
anthropometric and biological characteristics of each subject were compared to the
energy expenditure of each subject assessed by the IPAQ (27).
Correlations between energy expenditure determined by the IPAQ and the
anthropometric and biological characteristics were weak but significant. For both men
and women, the strongest correlations were found for vigorous leisure time PA and total
vigorous PA. In men, diastolic BP (r = -0.13 and -0.11, p<0.001), waist/hip ratio (r = 0.14 and -0.12, p<0.001), TG (r = -0.13 p<0.001, r = -0.07, p<0.05), HDL cholesterol (r
= 0.12 p<0.001, r = 0.08 p<0.01), and glucose (r = -0.07 and -0.07, p<0.05) were
significantly correlated with both vigorous leisure time PA and total vigorous PA,
respectively. BMI for men was only significantly correlated with vigorous leisure time
PA (r = -0.07, p<0.05). In women, diastolic BP (r = -0.08 and -0.07, p<0.01), BMI (r=0.09 p<0.001 and r=-0.06 p<0.05), waist/hip ratio (r = -0.09 p<0.01, r = -0.06 p<0.05),
TG (r = -0.12 and -0.12, p<0.001), HDL cholesterol (r = 0.07 p<0.05, r = 0.08 p<0.01)
and glucose (r = -0.12 and -0.10, p<0.001) were also significantly correlated with both
vigorous leisure time PA and total vigorous PA, respectively (27).
Washburn et al. (1991) examined the validity of the Harvard Alumni Activity
Survey by comparing subject responses to HDL cholesterol and BMI. In this study, 645
men and women between 25-65 yr completed the Harvard Alumni Activity Survey in
their home during a baseline interview and again during follow up interviews 7-12 wk
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later.

During the baseline interview, field researchers also obtained a series of

physiologic measurements including BP, height and weight. A single, non-fasted blood
sample was also obtained during the baseline interview for HDL and total cholesterol
measurements. Test-retest correlations for daily energy expenditure reported at baseline
and follow up was moderate (r = 0.58) for the sample as a whole. Pearson correlations
between the natural log values of reported energy expenditure and HDL cholesterol and
BMI were weak but statistically significant (r = 0.14 and -0.13 respectively, p<0.01).
These results suggest the Harvard Alumni Activity Survey is a valid and reliable tool for
assessing habitual PA (28).
The results of these studies show weak but significant correlations between selfreported PA and health outcomes known to be associated with PA. As a result, health
outcomes known to be associated with PA can be used, along with accelerometers and
CRF, to assess the ability of a questionnaire to accurately estimate PA.
Paffenbarger Physical Activity Questionnaire:

The PPAQ is an example of a

questionnaire used in epidemiological studies to assess PA and, therefore, must be
validated. The PPAQ, also commonly referred to as the College Alumni Questionnaire
and the Harvard Alumni Questionnaire, was designed to measure leisure time PA in
young and older adults (29). In its original form, the PPAQ asked respondents to report
the number of city blocks they walk and the number of flights of stairs they climb on a
typical day, as well as the frequency and type of any sports or recreational activities they
participated in over the past year (30). Using subject responses to these questions,
Paffenbarger et al. (1978) was able to estimate energy expenditure by calculating a PAI
(30).
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Since the development of the PPAQ, a number of studies have investigated the
validity of the PAI as an estimate of energy expenditure and PA. For instance, Ainsworth
et al. (1993) examined the validity of the PAI using a sample of 50 healthy women and
28 healthy men. This study consisted of 14 visits to the laboratory over a 12 month time
period.

Each study visit was separated by approximately 26 days.

Participants

completed the PPAQ during study visits 1, 8, and 9. Investigators computed the PAI for
each subject and compared it to measures of CRF, body fatness, PA data from an
accelerometer, and PA records (13).
In men, the PAI was significantly correlated with total and heavy intensity leisure
time PA measured by the PA records (r=0.60 and r=0.69 p<0.01, respectively) and
VO2max (r=0.55 p<0.01). In women, the PAI was also significantly correlated with total
and heavy intensity leisure time PA measured by the PA records (r=0.34 and r=0.65
p<0.01, respectively) as well as VO2max and percent body fat (r=0.53 p<0.01 and r=0.36
p<0.05, respectively) (13). However, the PAI scores from the PPAQ were lower than the
scores obtained from the PA records. This may be due to the fact that the PAI does not
assess activities of daily living, which often includes sedentary and light intensity
activities. The test-retest reproducibility of the PAI was highest after 1 month (r = 0.72)
and lower after 8 and 9 months (r = 0.35 and 0.43 respectively, p< 0.05). These results
suggest the PAI from the PPAQ is a moderately good tool for measuring habitual PA
status and it has acceptable short-term repeatability (13).
The current form of the PPAQ includes the questions that make up the PAI as
well as several additional questions regarding the frequency and intensity of PA the
respondent participates in (Appendix A). There are several studies in the literature
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examining the validity of the additional questions on the current form of the PPAQ. For
instance, the PPAQ Q6 asks, “At least once a week, do you engage in regular activity
akin to brisk walking, jogging, bicycling, swimming, etc. long enough to work up a
sweat, get your heart thumping, or get out of breath?” If the answer is yes, respondents
are asked to report the activity and the number of times per week they participate in the
activity. If the answer is no, respondents are asked to provide a reason as to why not.
Siconolfi et al. (1985) examined the relationship between the frequency of
participation in PA long enough to work up a sweat reported on the PPAQ Q6 and
VO2max in healthy men and women age 20-70 yr. The correlations for V02max and
frequency of participation in activities long enough to work up a sweat obtained in this
study were significant for men and the total group (r = 0.54 and 0.46, respectively
p<0.01). These results suggest CRF can be assessed rapidly in epidemiologic studies
using the PPAQ Q6 (31).
In addition to Q6, limited research is also available investigating the validity of
the PPAQ Q8. The PPAQ Q8 asks respondents to report how much time they spend
participating in PA of different intensities. Respondents are asked to report the number
of hours they spend on a typical week day and weekend day sleeping, sitting and
participating in light, moderate, and vigorous intensity PA.
Mahabir et al. (2006) examined the validity of the PPAQ Q8 as a tool for
assessing PA in a group of 65 post-menopausal women over 50 yr. Volunteers in this
study first completed the PPAQ Q8. The MET values assigned to the sleeping, light,
moderate, and vigorous PA intensity levels were 1, 2, 4, and 6, respectively. An average
METs/hr was calculated by multiplying the time (hrs) each subject reported sleeping and
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engaging in light, moderate, and vigorous intensity PA by the assigned MET values,
summing the four results, and dividing by the total hours in a week. Energy expenditure
(kcal/day) was measured for each subject using the Doubly Labeled Water method.
Daily energy expenditure estimated by the PPAQ Q8 was significantly correlated with
energy expenditure measured by the doubly labeled water method (r = 0.36, p<0.05).
However, compared with the doubly labeled water method, the PPAQ Q8 overestimated
energy expenditure (percent difference in the means was 62%) (32).
Similarly, Rundle et al. (2007) examined the validity of the PPAQ Q8 as a tool for
assessing PA in a group of 192 men and women age 18-74 yrs who were enrolled in a
larger study examining the effects of antioxidant micronutrients among cigarette
smokers. All volunteers in this sub-study were of low socioeconomic status and smoked
at least 10 cigarettes a day at the time of enrollment (43).
Volunteers in this sub-study completed the PPAQ Q8 during the 12-month visit of
the larger antioxidant micronutrients study. The MET values assigned to the sleeping,
sitting, light, moderate, and vigorous PA intensity categories were 0.9, 1, 3, 4.5, and 7,
respectively.

For each PA intensity category, the number of hours reported was

multiplied by the corresponding MET value to get a MET×hr score for a typical day
during the week and weekend. To estimate total weekly activity, the MET×hr score for
weekday activity was multiplied by 5 and the MET×hr score for weekend activity was
multiplied by 2, and the resulting quantities were summed. This resulted in an estimate
of energy expenditure expressed in units of MET×hr per week. After completing Q8,
each volunteer then had his or her BP measured. BMI (kg/m2) was calculated for each
subject using his or her height (m) measured at the time of enrollment and weight (kg)
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measured during the 12-month visit (43).
After controlling for age, gender, and number of cigarettes smoked per day,
weekly activity estimated by the PPAQ Q8 was significantly, inversely associated with
BMI, systolic BP, and diastolic BP (p=0.01) (43).
The results of the studies done by Mahabir and Rundle suggest the PPAQ Q8 is a
valid tool for assessing PA among men and women of low socioeconomic status, but
overestimates PA among post-menopausal women (32, 43). However, little information
is available regarding the validity and reliability of this question as a tool for assessing
PA in healthy men and women across the lifespan.
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Methods
STOMP Overview: This study investigated the validity and test-retest reliability of the
PPAQ Q8 using data from a larger study entitled, “The Effects of Statins on Muscle
Performance” (STOMP). STOMP was funded by the National Institutes of Health (NIH)
(1R01HL081893-01A2) and was conducted by
researchers at Hartford Hospital, the University
of Massachusetts, Amherst, and the University
of Connecticut, Storrs. The specific aims of
STOMP were to investigate the incidence rate
of statin-induced muscle symptoms, defined as
myalgia, as well as the effects of statins on
skeletal muscle strength, endurance, and
aerobic exercise performance in healthy men
and women taking either 80mg of Atorvastatin
(Lipitor) or placebo daily for six months. The
institutional review boards at all three of the
study sites approved the experimental design of
STOMP, which has been described in detail
elsewhere (34).
STOMP consisted of six visits to the
laboratory over a period of approximately six
months (Figure 1).

During study visit one

(V1), subjects provided a blood sample in the
Figure 1: Overview of STOMP study (34)
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fasted state. Subjects then completed several quality of life assessment forms, including
the PPAQ, and performed a series of elbow and knee flexion/extension isometric and
isokinetic strength tests using a Biodex System 3 isokinetic dynamometer (Biodex
Medical, Shirley, NY). Finally, subjects underwent a brief physical examination as well
as a physician supervised maximal graded treadmill test using a Bruce protocol with
electrocardiographic monitoring.
Study visit two (V2) occurred at least 72 hrs following V1. During V2, subjects
performed another series of elbow and knee flexion/extension isometric and isokinetic
strength tests on the Biodex.
maximal graded treadmill test.

CRF was measured using a modified Balke protocol
At the end of V2, subjects received an Actical

accelerometer and were instructed to wear it for at least four consecutive days (96 hrs)
including two days during the week and two days during the weekend.
Study visit three (V3) occurred at least 96 hrs following completion of V2.
During V3, subjects returned the Actical accelerometer and performed another series of
elbow and knee flexion/extension isometric and isokinetic strength tests on the Biodex.
At the end of V3, subjects received a three-month supply of either Atorvastatin or
placebo. Subjects were instructed to take two pills every evening for the next three
months. During the three-month time period, subjects were contacted every other week
by a study investigator to document the presence of any muscle symptoms associated
with statins.
Study visit four (V4) occurred approximately three months following the
completion of V3. During V4, subjects completed the PPAQ and provided a blood
sample in a non-fasted state. At the end of V4, subjects received another three-month
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supply of study medication and were instructed to continue taking two pills every
evening.

During the next three-month period, subjects were again contacted via

telephone every other week by a study investigator to document the presence of any
muscle symptoms associated with statins.
Study visit five (V5) occurred approximately three months following the
completion of V4. During this visit, subjects provided another blood sample in the fasted
state. Subjects then completed the PPAQ and performed another series of elbow and
knee flexion/extension isometric and isokinetic strength tests on the Biodex. CRF was
again measured using a modified Balke protocol maximal graded treadmill test. At the
end of V5, subjects received an Actical accelerometer and were instructed to wear it for
another four consecutive days (96 hrs) including two days during the week and two days
during the weekend.
Study visit six (V6) took place at least 96 hrs following the completion of V5.
During V6, subjects returned the Actical accelerometer. They then performed one last
series of elbow and knee flexion/extension isometric and isokinetic strength tests on the
Biodex.
PA measured by the Actical, CRF measured by VO2max, and health outcomes
associated with participation in PA collected during STOMP were used in this sub-study
to determine the concurrent and predictive validity and test-retest reliability of the PPAQ
Q8.
Subjects: Subjects for STOMP were recruited via study flyers, email announcements,
and radio/newspaper advertisements. Volunteers in STOMP included equal numbers of
men and women in the age groups 20-39, 40-54, and 55+ yr. Written informed consent
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was obtained from all subjects prior to participating (Appendix B). Individuals with
diabetes mellitus, hyper- or hypothyroidism, who had any kind of surgery or injury to the
knees or hips that would prevent the individual from exercising vigorously on a treadmill,
who were presently or had previously been treated with cholesterol-lowering
medications, or who had a heart condition that required medication or a restriction of
activity were excluded from participating in STOMP. Anyone with hepatic disease
(alanine aminotransferase> 2x the normal limit) or renal disease (creatinine> 2mg/L), as
determined by the fasted blood sample obtained during V1, or occult cardiac ischemia
documented during the physician-supervised treadmill test using a Bruce protocol with
electrocardiographic monitoring in V1 were also excluded from STOMP (34).
Individuals using hypertensive medications were included in the study so long as
they had been on the medication for at least three months and their BP was stable
(<140/90 mmHg). BP was monitored during V1 and V2 of STOMP to ensure each
subject’s eligibility. Women of childbearing age who participated in STOMP were given
a urine pregnancy test at the start (V1) and conclusion (V5) of the study and were asked
to use a type of contraception throughout the duration of their participation in the study
(34).
Sub-Study Procedures
Paffenbarger Physical Activity Questionnaire: Subjects completed the PPAQ for
the first time during V1. At the beginning of this visit, a STOMP study investigator gave
the PPAQ to the subject and explained how to properly complete the questionnaire.
Subjects were then instructed to take their time and complete the PPAQ to the best of
their ability. Once the subject finished completing the questionnaire, the investigator
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checked over the completed PPAQ to ensure there were no errors or omissions. If errors
or omissions were detected, the investigator clarified them with the subject.
Although STOMP subjects were asked to complete the entire PPAQ, only their
responses on Q8 were used in this sub-study. The PPAQ Q8 asks subjects to report the
number of hours they spent sleeping and participating in sitting activities and PA of light,
moderate and vigorous intensity on a typical day during the week and during the
weekend.

According to Q8, sitting activities include “eating, reading, desk work,

watching TV, listening to the radio, etc.”

Light intensity activities (<3 METs) are

defined as “office work, driving car, strolling, personal care, standing with little motion,
etc.” Moderate intensity activities (3-6 METs) are “housework, light sports, regular
walking, golf, yard work, lawn mowing, painting, repairing, light carpentry, ballroom
dancing, bicycling on level ground, etc.” Finally, vigorous intensity activities (>6 METs)
include “digging in the garden, strenuous sports, jogging, aerobic dancing, sustained
swimming, brisk walking, heavy carpentry, bicycling on hills, etc.” For this STOMP substudy, the concurrent and predictive validity of PPAQ Q8 were examined by comparing
subject responses on Q8 during V1 with measurements from an Actical accelerometer,
VO2max, and health outcomes.
V4 and V5 of STOMP occurred approximately three and six months following the
completion of V3, respectively. During these two visits, STOMP subjects completed the
PPAQ the same way they did during V1. For this sub-study, the test-retest reliability of
the PPAQ Q8 was examined by comparing subject responses on the PPAQ during V1
with their responses during V4 and V5 in a sample of subjects (n = 130) who were
randomized to receive the placebo during the STOMP study.
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In most situations, PA data collected using the PPAQ was analyzed exactly as
reported by the subject. However, in instances where a subject’s response to a section on
the questionnaire was not entirely clear, all study investigators used a set of strict
standard procedures to appropriately interpret and correct the data (Appendix C).
Health outcomes of PA: During V1, blood samples were collected from the
antecubital space on the arm of each subject. These blood samples were allowed to sit at
room temperature for at least 10 minutes. They were then centrifuged at 3400 rpm for 15
minutes (VanGuard V6500, Hamilton Bell Co., Inc., Montvale, NJ, USA). After the
blood samples were centrifuged, 1 mL aliquots of serum were obtained and shipped to
Clinical Laboratory Partners in Hartford, CT for serum lipid (ml/dL) analysis including
TC, TG, LDL and HDL cholesterol.
Following the blood draw during V1, subjects underwent a brief physical
examination with a physician. During this examination, the subject’s height and weight
were measured and recorded.

Prior to measuring height and weight, subjects were

instructed to remove their shoes and any heavy or bulky clothing, such as a jacket or
sweatshirt. Height was measured using a wall-mounted tape measure while the subject
stood erect with their head in the neutral position. Height was initially measured in
inches and then converted to centimeters by multiplying by 2.54. Weight was then
measured using a calibrated balance beam scale. Weight was initially measured in
pounds and then converted to kilograms by dividing by 2.2. From the height and weight
measurements, BMI was calculated (kg/m2).
Following the height and weight measurements, WC (cm) was measured using a
Gulick spring-loaded tape measure. With the subject standing, arms at their sides, feet
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together and abdomen relaxed, a horizontal measure was taken at the narrowest part of
the torso (above the umbilicus and below the xiphoid process). The study investigator
took two measurements. The average of the two measurements was used in this study,
provided the measurements were within 5 mm of one another. If the two measurements
were not within 5 mm of one another, the study investigator continued to take
measurements until he/she obtained two measurements that were within 5 mm of one
another.
Following the physical examination during V1, subjects completed a graded
treadmill test using a Bruce protocol to exclude individuals with occult ischemic coronary
artery disease. Prior to and at certain points during this treadmill test, BP (mmHg) and
HR (b/min) were measured. Resting BP (mmHg) was measured via auscultation using a
mercury sphygmomanometer (Trimline™, PyMaH Corp., Somerville, NJ, USA), a
Trimline BP cuff (Omni Kuff®, Latex Free, Universally connection BALANCED®
design, Trimline Medical Products, Somerville, NJ, USA) and a Cardiology stethoscope
(3M™ Litman® Lightweight II SE, St. Paul, MN, USA) while the subject sat with their
back and arms supported and their legs uncrossed. MAP (mmHg) was calculated from
the resting systolic and diastolic BP readings (MAP = Diastolic BP + 1/3(Systolic BP –
Diastolic BP)). Resting HR (b/min) was also measured while the subject was seated
using a HR monitor (Polar Vantage NV™ HR Monitor, Polor Electro Inc., Port
Washington, NY, USA).
Cardiorespiratory Fitness: CRF was measured during V2 and V5 of STOMP
using a modified Balke maximal treadmill test (4, 36, 37). Only CRF measured during
V2 was used in this study. VO2max (ml/dg/min) was determined by breath-by-breath
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analysis of expired gases via an open circuit respiratory apparatus (Parvomedics TrueOne
2400 metabolic cart, Parvomedics Corp, Sandy, UT, USA).
During the maximal treadmill test, subjects were asked to sit quietly for five
minutes prior to the start of the treadmill test. Following five minutes of seated rest,
subjects began the protocol by walking on the treadmill for two minutes at a speed of two
miles per hour and a 0% treadmill incline. Following these initial two minutes, the speed
of the treadmill was increased until the subject was running at a speed at which they
could comfortably maintain their natural stride for at least 30 minutes. This treadmill
speed remained constant throughout the remainder of the test. However, the incline of
the treadmill was increased by 1% after every minute. Periodically throughout the test,
the subject’s BP was measured, their HR was recorded, and the subject reported how hard
they were working using a rating of perceived exertion (RPE) from the 15 point Borg
scale (41). Treadmill test termination criteria included: an overall RPE ≥ 18, a plateau in
oxygen uptake, a respiratory exchange ratio>1.1, achievement of the age predicted
maximum HR (220 – subject’s age), and/or termination by the subject due to fatigue or
discomfort (4).
Actical Accelerometer: Subjects wore an Actical accelerometer between V2 and
V3 and again between V5 and V6. Only the Actical data collected between V2 and V3
was used in this study. At the end of V2, STOMP subjects received the Actical
accelerometer (Mini Mitter Company, Bend, OR, USA).

The Actical was securely

fastened to a hip clip allowing the subjects to wear the Actical attached to their belt or the
waistband of their pants. The device was set to record PA in 25-sec epochs and was
initialized to begin recording data immediately. The subjects were instructed to wear the
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Actical for at least four consecutive days (96 hrs; two days during the week and two days
over the weekend) and were told to only take the Actical off when they were swimming,
bathing, showering, or sleeping. If subjects removed the Actical to swim during the 96 hr
time period, they were asked to record the intensity and duration of their swim.
Subjects returned to the laboratory for V3 at least 96 hr following completion of
V2. During this visit, subjects returned the Actical accelerometer. The raw data from the
Actical accelerometer was downloaded immediately to a computer using a telemetrybased receiver that connects to the computer via a serial port connection. A STOMP
investigator quickly examined the raw data to ensure the accelerometer properly
registered the subject’s PA. If the Actical did not properly record a subject’s PA or if the
subject reported not wearing the Actical for 96 consecutive hrs, the subject was asked to
wear the monitor for another four consecutive days.
If the Actical properly recorded the subject’s PA, the raw data was then exported
to Microsoft Excel for further processing and analysis. From the raw data obtained from
the Actical, the average number of daily steps (d-1), activity counts (d-1), energy
expenditure (kcal/day), and average daily time (min/d) spent being sedentary and
engaging in light, moderate, and vigorous intensity PA was calculated.
Data Administration: Data collected during the STOMP study was compiled in an
online master database, which was maintained by the study coordinator (BAP) at
Hartford Hospital, Hartford, CT.

Investigators from each of the three study sites

manually entered STOMP data into the online database. Access to the database was
limited to study personnel and was secured using confidential usernames and passwords.
Statistical Analysis: Prior to any statistical analysis, from the PPAQ Q8, the number of
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hours subjects reported spending sleeping and sitting were added to obtain the number of
hours on a typical day during the week and a typical day during the weekend subjects
spend sedentary. For example:

Then, for each PA intensity category on the PPAQ Q8, the number of hours
reported for a typical day during the week and a typical day during the weekend were
averaged to obtain the average number of hours subjects spend being sedentary and
engaging in light, moderate, and vigorous intensity PA. For example:

Descriptive statistics were then calculated on all study variables and were
reported as the mean±standard error of the mean (SEM).
Hypothesis 1 (Concurrent Validity): To determine the concurrent validity of the
PPAQ Q8, Pearson product-moment correlation coefficients were calculated to assess the
relationships among average self-reported time (hr/d) spent being sedentary and engaging
in light, moderate, and vigorous intensity PA on the PPAQ Q8 during V1 and average
daily steps (d-1), activity counts (d-1), energy expenditure (kcal/d), and time (min/d) spent
in each PA intensity category measured with the Actical accelerometer.

For any

relationship that was significant, multivariable regression analysis was used to determine
the influence of age, gender, and season during which the PPAQ Q8 was completed
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during V1 on the relationship. All multivariable regression models were zero-centered to
limit the likelihood of multicollinearity.
Hypothesis 2 (Predictive Validity): To examine the predictive validity of the
PPAQ Q8, Pearson product-moment correlation coefficients were calculated to examine
the relationships among average self-reported time (hr/d) spent being sedentary and in
light, moderate, and vigorous intensity PA on the PPAQ Q8 during V1 and CRF,
measured by VO2max (ml/kg/min).

For any relationship that was significant,

multivariable regression analysis was used to determine the influence of age, gender, and
season during which the PPAQ Q8 was completed during V1 on the relationship. All
multivariable regression models were zero-centered to limit the likelihood of
multicollinearity.
Hypothesis 3 (Predictive Validity): To further examine the predictive validity of
the PPAQ Q8, Pearson product-moment correlation coefficients were calculated to
examine the relationships among average self-reported time (hr/d) spent in each PA
intensity category on the PPAQ Q8 during V1 and various health outcomes, including
resting BP, MAP, TG, TC, LDL and HDL cholesterol, resting HR, BMI, and WC. For
any relationship that was significant, multivariable regression analysis was used to
determine the influence of age, gender, and season during which the PPAQ Q8 was
completed during V1 on the relationships. All multivariable regression models were
zero-centered to limit the likelihood of multicollinearity.
Hypothesis 4 (Test-Retest Reliability): To determine the test-retest reliability of
the PPAQ Q8, Pearson product moment correlation coefficients were calculated to
compare self-reported time (hr/d) spent in each PA intensity category on the PPAQ Q8
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during V1 with self-reported time (hr/d) spent in each PA intensity category on the PPAQ
Q8 during V4 and V5. Pearson product moment correlation coefficients were also used
to compare average self-reported time (hr/d) spent in each PA intensity category on the
PPAQ Q8 during V4 with average self-reported time (hr/d) spent in each PA intensity
category on the PPAQ Q8 during V5. A repeated measures ANCOVA, with gender and
season during which subjects completed the PPAQ Q8 during V1 as fixed factors and age
as a covariate, was used to examine whether or not average self-reported time (hr/d) spent
in each PA intensity category on the PPAQ Q8 was significantly different at three and six
months.
All statistical analyses were performed with the Statistical Package for the Social
Sciences (SPSS) Base 14.0 for Windows (SPSS Inc, Chicago, IL) with p<0.05
established as the level of statistical significance.
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Results
PPAQ Q8 Validity
Subject Characteristics: The sample for the validity portion of this sub-study (n=240)
consisted of mostly young, healthy, Caucasian (85.8%) men (n=118) and women (n=122)
(Table 4). Subjects were overweight with above optimal LDL cholesterol, optimal BP,
desirable TC; and normal MAP, HDL cholesterol, and TG. Men were heavier (p=0.000)
and had higher BP (p=0.000), WC (p=0.000), and TG (p=0.005), and a lower resting HR
than women (p=0.002).

Women, however, had higher HDL cholesterol than men

(p=0.000) (Table 4).

Table 4. Subject Characteristics (Mean ± SEM)
Total
Characteristics
(n=240)
39.6 ± 0.9
Age (yr)
1.7 ± 0.1
Height (m)
Weight (kg)
77.9 ± 1.1
2
26.3
± 0.3
BMI (kg/m )
116.8 ± 0.9
Systolic Blood Pressure (mmHg)
74.7 ± 0.6
Diastolic Blood Pressure (mmHg)
88.7 ± 0.7
Mean Arterial Pressure (mmHg)
69.7 ± 0.8
Resting Heart Rate (b/min)
85.2 ± 0.9
Waist Circumference (cm)
VO2max (ml/kg/min)
35.3 ± 0.6
High Density Lipoprotein Cholesterol
57.5 ± 1.1
(mg/dL)
Low Density Lipoprotein Cholesterol
113.9 ± 2.2
(mg/dL)
Total Cholesterol (mg/dL)
191.7 ± 2.6
102.8 ± 3.8
Triglycerides (mg/dL)
Men vs. Women: ψ p<0.01, *p<0.001

Men
(n=118)
40.1 ± 1.4
1.8 ± 0.1*

Women
(n=122)
39.1 ± 1.3
1.7 ± 0.0

87.3 ± 1.4*
27.4 ± 0.4*
120.2 ± 1.2*
76.5 ± 0.9ψ
91.1 ± 0.9*
67.4 ± 1.1 ψ
91.9 ± 1.3*
39.5 ± 0.8
51.0 ±1.4*

68.9 ± 1.2
25.3 ± 0.4
113.5 ± 1.1
72.9 ± 0.8

118.3 ± 2.9

109.9 ± 3.3

191.9 ± 3.3
113.9 ± 6.5 ψ

191.4 ± 3.9
92.6 ± 4.1

86.5 ± 0.9
71.9 ± 1.1
79.1 ± 1.1
31.4 ± 0.8
63.3 ± 1.6

Specific Aim 1: The first specific aim of this STOMP sub-study was to assess the
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concurrent validity of the PPAQ Q8 by examining the relationships among self-reported
PA on the PPAQ Q8 during V1 and the Actical accelerometer measurements. The
average min/d subjects spent being sedentary and engaging in light, moderate, and
vigorous intensity PA measured with the Actical accelerometer by age group is shown in
Table 5. Subjects spent the most amount of time (min/d) being sedentary, followed by
light and moderate, and the least amount of time in vigorous intensity PA (p=0.000).
Individuals in the youngest age group had a tendency to spend more min/d in moderate
intensity PA than individuals in the oldest age group (p=0.085) (Table 5).

Table 5. Average Daily Time (min/d) (Mean ± SEM) Spent in each Physical Activity
Intensity Category Measured with the Actical by Age Group
Vigorous
Light
Moderate
Intensity*
Intensity*
Intensity*
Sedentary*
≥6 METs)
Age Group (yr)
(1 – <1.5 METs) (1.5 – 3 METs) (3 – 6 METs) (≥
20-29
1088.8 ± 11.4
202.3 ± 6.8
143.9 ± 5.7
5.0 ± 0.9
30-48
1084.5 ± 11.1
219.5 ± 6.7
133.4 ± 5.9
2.6 ± 0.7
49-82
1103.1 ± 11.9
206.5 ± 7.4
126.5 ± 5.7
3.9 ± 1.1
*Sedentary vs. Light vs. Moderate vs. Vigorous p=0.000, independent of age

There was a positive association between average self-reported hr/d spent
engaging in vigorous intensity PA on the PPAQ Q8 during V1 and average daily activity
counts (d-1) measured with the Actical (p=0.022). Additionally, average self-reported
hr/d spent being sedentary and engaging in moderate and vigorous intensity PA on the
PPAQ Q8 during V1 was positively associated with average min/d spent being sedentary
and in moderate and vigorous intensity PA measured with the Actical accelerometer
(sedentary p=0.005, moderate p=0.000, vigorous p=0.045, respectively). Age, gender,
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and season during which the PPAQ Q8 was completed did not influence these
relationships (p>0.05) (Table 6).
Table 6. Correlations among Intensity Categories on the Paffenbarger Physical
Activity Questionnaire Question Eight Completed during Visit One and the Actical
Accelerometer Measurements
Light
Moderate Vigorous
Actical Measurements
Sedentary Intensity Intensity Intensity
Average Steps (day-1)
0.022
0.077
0.089
-0.147*
-1
0.085
0.013
-0.192*
0.149*
Average Activity Counts (day )
Average Energy Expenditure (kcal/d)
0.032
0.072
0.096
-0.168**
-0.177
0.143*
-0.306**
0.183**
Sedentary (min/d)
Light Intensity (min/d)
-0.235
-0.066
0.075
0.313**
Moderate Intensity (min/d)
-0.089
0.121
0.233**
-0.187**
0.070
-0.102
-0.045
0.130*
Vigorous Intensity (min/d)
*p<0.05, **p<0.01

Specific Aim 2: The second specific aim of this STOMP sub-study was to assess
the predictive validity of the PPAQ Q8 by comparing self-reported hr/d in each PA
intensity category on Q8 and CRF, measured by VO2max. Average self-reported hr/d
spent in vigorous intensity PA on the PPAQ Q8 during V1 was positively correlated with
VO2max (r=0.134, p=0.026).
Specific Aim 3: The third specific aim of this sub-study of STOMP was to further
assess the predictive validity of the PPAQ Q8 by comparing self-reported PA on Q8
during V1 and various health measures. Weak, negative associations were observed
between average self-reported hr/d spent in moderate intensity PA on the PPAQ Q8
during V1 and WC (p=0.027), systolic BP (p=0.007), MAP (p=0.030), and TG
(p=0.046). Similarly, weak, negative associations were observed between average selfreported hr/d spent in vigorous intensity PA on the PPAQ Q8 during V1 and diastolic BP
(p=0.037) and BMI (p=0.004).

Weak, positive associations were observed between
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average self-reported hr/d spent in moderate and vigorous intensity PA on the PPAQ Q8
during V1 and HDL cholesterol (moderate p=0.005; vigorous p=0.000) (Table 7).
Table 7. Correlations among Intensity Categories on the Paffenbarger Physical
Activity Questionnaire Question Eight Completed during Visit One and Various
Health Measures

BMI (kg/m2)

0.128*

Light
Intensity
0.045

Resting Heart Rate (b/min)

0.021

0.088

Waist Circumference (cm)
Systolic Blood Pressure (mmHg)

0.091
0.180**

0.081
-0.024

-0.150*
-0.176**

-0.109
-0.068

Diastolic Blood Pressure (mmHg)

0.142*

-0.020

-0.100

-0.135*

0.170**
-0.162*

-0.023
-0.106

-0.141*
0.187**

-0.116

Health Outcomes

Mean Arterial Pressure (mmHg)
High Density Lipoprotein Cholesterol
(mg/dL)
Low Density Lipoprotein Cholesterol
(mg/dL)
Total Cholesterol (mg/dL)
Triglycerides (mg/dL)
p<0.05*, p<0.01**

Sedentary

Moderate
Intensity
-0.122

Vigorous
Intensity
-0.185**

-0.056

-0.112

0.275**

-0.089

0.109

-0.003

0.005

-0.127
0.110

0.062
0.034

0.046

0.110
-0.070

-0.134*

Multivariable regression analysis examined the influence of age, gender, and
season on the relationships among the health measures described above in specific aims 2
and 3 and average self-reported hr/d spent in each PA intensity category on the PPAQ Q8
during V1 (Table 8). Women who were older, had a lower BMI, and completed the
PPAQ Q8 during the summer and fall months reported spending more hr/d in moderate
intensity PA (F=5.722, p=0.001). Additionally, men and women who were older, had a
higher VO2max and a lower diastolic BP, and completed the PPAQ Q8 during the
summer and fall months reported spending more time in vigorous intensity PA (F=7.910,
p=0.000) (Table 8).
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Table 8. The Influence of Age, Gender, and Season on the Relationships among
Health Measures and Self-Reported Time (hr/d) Spent in Moderate and Vigorous
Intensity Assessed with the Paffenbarger Physical Activity Questionnaire Question
Eight
Moderate Intensity

β-value

p-value

0.459

0.017

-0.673
0.273
F=5.722

0.001
0.003
p=0.001

β-value

p-value

0.022
0.031
-0.013
0.149
F=7.190

0.000
0.000
0.052
0.002
p=0.000

Predictors
Age (yr)
2

Body Mass Index (kg/m )
Season
Overall Model
Vigorous Intensity
Predictors
Age (yr)
VO2max (ml/kg/min)
Diastolic Blood Pressure (mmHg)
Season
Overall Model

PPAQ Q8 Reliability
Subject Characteristics: Subjects (n=130) in the STOMP study who were randomized to
receive the placebo participated in the reliability portion of this sub-study. Descriptive
characteristics for these subjects are shown in Table 9, and they did not differ from those
of the subjects participating in the validity portion of this sub-study (p>0.05). Similar to
the subjects in the validity portion of this sub-study, men were heavier (p=0.007) and had
a higher systolic BP (p=0.017), MAP (p=0.036), and VO2max (p=0.000) than women.
Women on the other hand were older than the men (p=0.043) (Table 9).
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Table 9. Subject Characteristics (Mean ± SEM)
Total (n=130)

Men (n=63)

39.9 ± 1.2

37.4 ± 1.7γ

Women
(n=79)
41.9 ± 1.5

Height (m)

1.7 ± 0.1

1.8 ± 0.1*

1.7 ± 0.1

Weight (kg)

76.9 ± 1.4

86.9 ± 1.9*

69.0 ± 1.4

BMI (kg/m2)

26.2 ± 0.4

27.3 ± 0.6ψ

25.3 ± 0.5

Systolic Blood Pressure (mmHg)

115.1 ± 1.0

118.2 ± 1.7ψ

112.6 ± 1.2

Diastolic Blood Pressure (mmHg)

74.3 ± 0.8

75.9 ± 1.2

73.1 ± 1.1

Mean Arterial Pressure (mmHg)

87.9 ± 0.8

90.1 ± 1.3ψ

86.2 ± 1.0

VO2max (ml/kg/min)

34.1 ± 0.8

40.4 ± 1.1*

29.1 ± 0.9

Characteristics
Age (yr)

Men vs. Women, γp<0.05, ψ p<0.01, *p<0.001

Specific Aim 4: The fourth specific aim of this STOMP sub-study was to examine the
test-retest reliability of the PPAQ Q8 measured at baseline and then again at three and six
months. To achieve this aim, subjects completed the PPAQ Q8 during V1 (baseline) then
again during V4 (three months) and V5 (six months). Pearson product moment
correlation coefficients were calculated to examine the relationships among average selfreported hr/d spent in each PA intensity category on Q8 during V1 and V4, V4 and V5,
and V1 and V5 (Table 10).
Moderately strong, positive associations were observed between V1 and V4, V4
and V5, and V1 and V5 for average self-reported hr/d spent being sedentary (p=0.000);
and in light (p=0.000), moderate (p=0.000), and vigorous (p=0.000) intensity PA (Table
10).
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Table 10. Correlations among Intensity Categories on the Paffenbarger Physical
Activity Questionnaire Question Eight Completed during Visit One and Visit Four,
Visit Four and Visit Five, and Visit One and Visit Five
Physical Activity
Intensity Category

V1 vs. V4*

V4 vs. V5*

V1 vs. V5*

Sedentary

0.390

0.496

0.548

Light Intensity

0.390

0.384

0.369

Moderate Intensity

0.500

0.258

0.359

Vigorous Intensity

0.282

0.548

0.362

For all variables, p<0.001*

The average self-reported hr/d subjects spent in each PA intensity category on
PPAQ Q8 during V1, V4, and V5 is shown in Table 11. A repeated measures ANCOVA
showed there was no significant within-subjects effect on average self-reported hr/d spent
being sedentary (F=0.782, p=0.387) and engaging in light (F=0.021, p=0.884), moderate
(F=0.004, p=0.950), and vigorous (F=0.633, p=0.428) intensity PA on Q8 on V1, V4 and
V5. Furthermore, there was no significant within-subjects effects of age, gender, and
season on average self-reported hr/d spent being sedentary and engaging in moderate and
vigorous intensity PA on PPAQ Q8 on V1, V4, and V5 (Table 11). There was, however,
a significant within-subjects effect of age on average self-reported hr/d spent engaging in
light intensity PA (p=0.003).
ANCOVA showed there was no significant between-subjects effects of age,
gender, or season on average self-reported hr/d spent being sedentary and engaging in
moderate and vigorous intensity PA on Q8 during V1, V4, and V5 (p>0.05). However,
there was a significant between-subjects (p=0.003) effect of age on average self-reported
hr/d spent in light intensity PA on the PPAQ Q8 on V1, V4, and V5 such that as age
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increased averaged self-reported hr/d spent engaging in light intensity PA increased
(Table 11).
Table 11. Average Time (hr/d) (Mean±
±SEM) Spent in Physical Activity Intensity
Category Reported on Question Eight on Visit One, Visit Four, and Visit Five
Physical Activity
Intensity Category

Visit One
(hr/d)*

Visit Four
(hr/d)*

12.9 ± 0.3

13.0 ± 0.3

12.6 ± 0.3

Light Intensity

5.3 ± 0.2

5.1 ± 0.2

5.4 ± 0.2

Moderate Intensity

4.3 ± 0.2

4.2 ± 0.2

4.5 ± 0.3

Vigorous Intensity

1.5 ± 0.1

1.6 ± 0.1

1.7 ± 0.1

Sedentary

For each PA intensity category V1 vs. V4 vs. V5, p>0.05*
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Visit Five
(hr/d)*

Discussion
The purpose of this STOMP sub-study was to examine the concurrent and
predictive validity as well as the test-retest reliability of the PPAQ Q8 among healthy
men and women across the lifespan. The results of this STOMP sub-study show
significant associations among PA reported on Q8 and measurements from an Actical
accelerometer, VO2max, and various health outcomes. Furthermore, the results of this
study show PA assessed by the PPAQ Q8 is consistent when measured three and six
months from baseline.
PPAQ Q8 Validity
Specific Aim 1: The first specific aim of this STOMP sub-study was to examine
the concurrent validity of the PPAQ Q8 by comparing subject responses on Q8 with PA
measurements from an Actical accelerometer. The original hypothesis stated that selfreported time (hr/d) spent in moderate and vigorous intensity PA on the PPAQ Q8 would
be positively correlated with average daily steps (d-1), activity counts (d-1), and energy
expenditure (kcal/d) as measured by an Actical accelerometer. It was also hypothesized
that self-reported time (hr/d) spent in each PA intensity category on the PPAQ Q8 would
be positively associated with average min/d spent in each PA intensity category as
measured by the Actical accelerometer.
A weak, positive association between self-reported hr/d spent in vigorous
intensity PA on the PPAQ Q8 during V1 and average daily activity counts (d-1) was
observed (r=0.149, p=0.022). Moreover, weak positive associations (r=0.130-0.233)
were also observed among average self-reported hr/d spent being sedentary and in
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moderate and vigorous intensity PA on the PPAQ Q8 and min/d spent being sedentary
and in moderate and vigorous intensity PA measured with the Actical accelerometer.
Although the observed associations are weak, previously published studies have
reported correlations of similar magnitude between self-reported PA and PA measured
with an accelerometer. Wolin et al (2008) found correlations ranging from r=0.26-0.36
among self-reported PA on the short version of the IPAQ and PA measured with an
Actical accelerometer in a group of healthy African American men and women age 24-70
yr (25). Similarly, Strath et al. (2004) reported correlations among self-reported PA on
the PPAQ PAI and PA measured using the simultaneous heart-rate motion sensor
technique ranging from r=0.20-0.47 in a group of men and women in a slightly younger
sample (20-56 yr) (1). Finally, Hagstromer et al. (2008) and Boon et al. (2010) reported
fairly weak associations among self-reported PA on the IPAQ and PA measured by the
Actigraph accelerometer ranging from r=0.14 – 0.27 and r=0.19-0.30, respectively (46,
47).
In this STOMP sub-study, the associations among self-reported PA on the PPAQ
Q8 and the measurements from the Actical accelerometer (ranging from r=0.130-0.233)
agree with the hypothesis and are consistent with the literature. This indicates the PPAQ
Q8 has adequate concurrent validity among healthy men and women over the age of 20
yr.
Specific Aim 2:

The second specific aim of this STOMP sub-study was to

examine the predictive validity of the PPAQ Q8 by comparing subject responses on Q8
and CRF, measured by VO2max (ml/kg/min). The original hypothesis stated that self-
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reported time (hr/d) spent in vigorous intensity PA on the PPAQ Q8 would be positively
correlated with VO2max (ml/kg/min).
As hypothesized, a positive association between self-reported time (hr/d) spent in
vigorous intensity PA on the PPAQ Q8 and VO2max (ml/kg/min) was observed (r=0.134,
p=0.026).

This association is in agreement with previously published studies.

For

instance, Aadahl et al. (2006) reported a strong, significant association between the
amount of daily vigorous intensity PA reported on a newly developed and validated PA
questionnaire and VO2max (r=0.87, p=0.0001) in a group of 102 healthy men and women
age 35-65 yr (12). Similarly, Richardson et al (2001) observed strong associations on the
Stanford 7-day recall on two separate occasions between VO2max and total PA as well as
very hard (≥7 METs) PA in men (Total PA: r=0.49, p<0.01 and r=0.54, p<0.01; Very
hard: r=0.48, p<0.05 and r=0.62, p<0.01) and women (Total PA: r=0.14, NS and r=0.47,
p<0.01; Very hard: r=0.24, NS and r=0.42, p<0.01) aged 21-59 yr (19). Finally, Kurtze
et al. (2008) reported a positive correlation of moderate strength between time spent in
vigorous intensity PA reported on a PA questionnaire and VO2max (r=0.46, p<0.01) in a
group of men age 20-39 yr (20).
The association between self-reported hr/d spent in vigorous intensity PA and
VO2max (r=0.134, p=0.026) in this STOMP sub-study is consistent with the original
hypothesis, but is weaker than what is reported in the literature. Therefore, this indicates
acceptable predictive validity of the PPAQ Q8 among healthy men and women across the
lifespan as compared to VO2max.

However, it must be noted that self-report

questionnaires measure participation in PA, whereas VO2max measures fitness. Fitness
is determined to an extent by participation in vigorous intensity PA, but is also influenced
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by genetics and environmental factors (49). Therefore, VO2max must be used to validate
Q8 in conjunction with other validation methods.
Specific Aim 3: The third specific aim of this STOMP sub-study was to further
examine the predictive validity of the PPAQ Q8 by comparing average self-reported hr/d
spent in each PA intensity category on Q8 and various health outcomes. The original
hypothesis was that negative associations would be observed between average selfreported time (hr/d) spent in moderate and vigorous intensity PA on the PPAQ Q8 and
BMI, systolic and diastolic BP, WC, TG, TC, LDL cholesterol, and resting HR. It was
also hypothesized that a positive association would be observed between average selfreported time (hr/d) spent in moderate and vigorous intensity PA on the PPAQ Q8 and
HDL cholesterol.
As hypothesized, there were a number of significant negative associations
observed for self-reported time (hr/d) spent in moderate and vigorous intensity PA and
objective health outcome measures; specifically BMI, WC, systolic and diastolic BP,
MAP, and TG, ranging from r= -0.134 to -0.185. Furthermore, positive associations
were observed between average self-reported hr/d spent in both moderate and vigorous
intensity PA and HDL cholesterol (r=0.187 and r=0.275, p<0.001), respectively.
The direction and magnitude of these correlations agrees with previously
published studies. Graff-Iversen et al. (2007) reported weak yet significant correlations
between self-reported PA on the long version of the IPAQ and health outcomes (BMI,
HDL cholesterol, waist/hip ratio, TG, diastolic BP, and glucose) ranging from r= -0.140.12 in a group of men and women age 31-67 yr (27). Washburn et al. (1991) also found
weak but significant associations between self-reported energy expenditure on the PPAQ
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PAI and HDL cholesterol and BMI (r=0.14 and r=-0.13 p<0.01) in a group of men and
women age 25-65 yr (28).
The associations between self-reported PA and health outcomes observed in this
STOMP sub-study agree with both the hypotheses and the literature. These findings lend
additional support that the PPAQ Q8 has acceptable predictive validity among healthy
men and women across the lifespan.
PPAQ Q8 Reliability
Specific Aim 4: The fourth specific aim of this STOMP sub-study was to examine
the test-retest reliability of the PPAQ Q8 measured at baseline and then again at three and
six months. The original hypothesis was average self-reported time (hr/d) spent in each
PA intensity category on the PPAQ Q8 during V1 would not be significantly different
from average self-reported time (hr/d) spent in each PA intensity category on the PPAQ
Q8 during V4 and V5.
Moderately strong correlations were observed between PA reported on Q8 during
V1 and V4 (baseline and three months), V4 and V5 (three months and six months), and
V1 and V5 (baseline and six months) for each PA intensity category, with values ranging
from r=0.282-0.548 for reliability over a three month time period and r=0.359-0.548 for
reliability over a six month time period.
The correlations between self-reported time in each PA intensity category on the
PPAQ Q8 during V1, V4, and V5 agree with the results of other previously published
studies. For instance, Ainsworth et al. (1993) reported similar reliability over an eight
and nine month time period for the PPAQ PAI (r=0.34 and r=0.43 p<0.05) in a group of
men and women of similar age to subjects in this STOMP sub-study (13). Likewise,
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Richardson et al. (2001) reported similar observations on the test-retest reliability over a
one month period of time of the Stanford 7-day recall in 78 healthy men and women
(r=0.60, p<0.01 and r=0.36, p<0.05,) age 21-59 yr (19).

In addition, the repeated

measures ANCOVA demonstrated there was no significant difference between average
hr/d spent in each PA intensity category reported by the same subjects on the PPAQ Q8
during V1, V4, and V5.
The correlations between self-reported PA on the PPAQ Q8 during V1, V4, and
V5 and the results of the repeated measures ANCOVA are consistent with both the
original hypothesis and the literature.

The PPAQ Q8 demonstrated good test-retest

reliability for PA assessments made at baseline, three and six months.
Study Significance
The purpose of this STOMP sub-study was to assess the validity and reliability of
the PPAQ Q8. Questionnaires are a desirable tool to assess and measure participation in
PA because they are relatively inexpensive and easy to administer to large groups of
people (1,2,12,13). However, questionnaires must be shown to be valid and reliable
before they can be used to assess PA. To the best of the author’s knowledge, this is the
first study performed which examined the criterion and predictive validity as well as the
test-retest reliability of the PPAQ Q8 using a sample of healthy men and women across
the lifespan.
The results of this study provide novel evidence that, among healthy men and
women over the age of 20 yr, the PPAQ Q8 has adequate concurrent validity, acceptable
predictive validity, and good test-retest reliability. These findings are significant because
the PPAQ Q8 allows researchers and health/fitness professionals to assess PA in ways
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that the other components of the PPAQ cannot. For instance, other components of the
PPAQ (i.e., the PAI and Q6) are able to accurately measure participation in moderate and
vigorous intensity PA, but are unable to accurately reflect participation in sedentary or
light intensity PA (1). The PPAQ Q8 inquires about participation in PA of all intensities.
This allows researchers and health/fitness professionals to examine participation in
sedentary and light intensity activities as well as moderate and vigorous intensity PA,
thus providing the clinician with a more complete representation of the individual’s
habitual PA.
Additionally, including Q8 in the PPAQ PA assessment battery allows clinicians
to assess an individual’s participation in PA using the complete FITT principle of
exercise prescription. The other components of the PPAQ are capable of accurately
assessing PA in terms of the frequency (Q6), intensity (Q7), and type (Q4 and Q6)
components of FITT. Since the results of this sub-study show the PPAQ Q8 is both
accurate and valid, it can be used to assess PA in terms of the Time component of the
FITT. Ultimately, Q8 will help clinicians determine whether or not healthy adults are
meeting the recommended 150 min/wk of moderate or 75 min/wk of vigorous intensity
PA recommended by the USDHHS.
Potential Study Limitations
This STOMP sub-study is limited by several factors. The data used in this
STOMP sub-study were collected at multiple test sites. This increased the chances of site
and interpretation bias occurring during the data collection and entry processes.
However, investigators at each of the three sites followed a strict standard protocol for
collecting data as well as for interpreting subject responses on the PPAQ during data
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entry (Appendix C).

Investigators from each study site also attended a mandatory

monthly staff meeting to discuss study progress and ensure investigators at each site were
accurately following the study protocol, limiting the opportunity for bias during data
collection and subsequent entry (34). These actions likely decreased the amount of site
and interpretation bias that may have occurred.
Additionally, only individuals who were identified as “healthy,” according to the
inclusion/exclusion criteria of the STOMP study, who could exercise vigorously on a
treadmill, and who were willing to take either Lipitor or placebo for six months
participated in STOMP. As a result, the sample used in this STOMP sub-study was selfselected as opposed to a true random sample. However, despite the fact that it was selfselected, the sample used in this sub-study is representative of the general population.
Therefore, the results of this study are applicable to the general population.
Finally, one of the major limitations to using questionnaires to assess participation
in PA is their increased tendency to misclassify PA compared with objective methods of
assessing PA (15). Despite the evidence in specific aims 1-4 that PPAQ Q8 is both valid
and reliable, a multivariable regression analysis used in this sub-study demonstrated that
older subjects are more likely to report spending the most time in moderate and vigorous
intensity PA (p=0.000). This contradicts the findings of previously published studies.
For instance, in Healthy People 2010, the USDHHS reported that as age increased,
participation in all types of PA decreased (46). Additionally, Macera et al. (2001)
analyzed data from the 2001 Behavioral Risk Factor Surveillance System and reported
that participation in both moderate and vigorous intensity PA decreased with increasing
age (47). Furthermore, Ayabe et al. (2009) measured PA in both younger (18-29 yr) and
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older (50-69 yr) adults with an accelerometer. They found younger adults spent the most
time in moderate to vigorous intensity PA (p<0.01) when compared to the older adults,
who spent more time in light intensity PA (p<0.05) (45). The disagreement between the
multivariable regression analysis in this sub-study and the previously published literature
illustrates the tendency of PA questionnaires to misclassify PA.
Study Strengths
There are several strengths to this STOMP sub-study. First, previously published
studies assessing the ability of questionnaires to measure and assess participation in PA
sometimes only focus on one dimension of validity, such as concurrent or predictive
validity. Moreover, questionnaire validation studies often times neglect to examine the
test-retest reliability of the questionnaire altogether (1, 2, 12, 27). This study focused on
the concurrent and predictive validity as well as the test-retest reliability of the PPAQ Q8.
Therefore, the results of this study provide more complete and accurate evidence that the
PPAQ Q8 is indeed a valuable tool for assessing participation in PA.
Second, this STOMP sub-study utilized data collected from a large sample
(n=240) of healthy men and women. The sample used in this study was larger and
covered a wider age range (20-81 yr) than a number of other studies in the literature
examining the validity and/or test-retest reliability of other PA questionnaires.

The

larger sample size and wider age range used in this study increases the accuracy of the
results and allows the findings/conclusions to be generalized to a larger group of people.
Additionally, all measurements were obtained using either the gold standard for
the specific test or well-accepted procedures often cited in the literature. For example,
CRF was measured using VO2max, BP was measured via auscultation, WC was
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measured with a Gulick spring-loaded tape measure at the narrowest part of the torso, and
PA was measured using an accelerometer for at least four days. All equipment used in
this study, including BP cuffs, Actical accelerometers, and HR monitors were calibrated
prior to their use. Furthermore, investigators from each testing site followed a strict
standard operating procedure and frequently conducted quality control tests to ensure all
measurements were accurate and reliable. The above quality control measures helped to
minimize site and interpretation bias during the data collection processes.
Lastly, the STOMP study was conducted by a strong research team composed of
internationally known experts in muscular and cardiovascular physiology and physical
activity assessment from Hartford Hospital, the University of Massachusetts Amherst,
and the University of Connecticut Storrs.

Each investigator on the research team

possessed extensive experience in designing and executing randomized control trials,
increasing the likelihood that the results and conclusions of this STOMP sub-study are
indeed accurate.
Conclusion/Future Directions
The results of this STOMP sub-study suggest that the current form of the PPAQ
Q8 has adequate concurrent validity, acceptable predictive validity, and good test-retest
reliability. However, as is the case with most self-report PA questionnaires, the
associations among average self-reported hr/d spent in each PA intensity category on
PPAQ Q8 and objectively measured PA and health/fitness measures were generally
weak. This indicates that, although it is currently a valid and reliable tool, future research
should be done to further improve its validity and reliability.
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First, the first four questions on the PPAQ ask respondents to report the PA they
participated in over a specific time period. For instance, question four of the PPAQ asks
respondents to “List any sports or recreation you have actively participated in during the
past year.” Stating a specific time period helps to ensure respondents are accurately
reporting their current PA participation. Currently, the PPAQ Q8 states, “On a usual
weekday and a weekend day, how much time do you spend on the following activities?”
It does not specify over what time period subjects should be reporting their average daily
activity.

Specifying a time period might help to further improve the validity and

reliability of PPAQ Q8. Therefore, future research should be done to examine whether or
not re-wording the instructions on the PPAQ Q8 to include a time period, such as over
the past week or over the past year, increases the validity and reliability of Q8.
Second, on the PPAQ Q8, examples are given for each PA intensity category.
However, these examples do not take into consideration the fact that age has an impact on
the intensity of an activity for a given person (48). For example, regular walking is used
as an example of moderate intensity PA. This activity may be of moderate intensity for
an older adult, but this same activity may constitute a lighter intensity for a younger adult
and may cause confusion during reporting (48).
Future research should be done to develop different versions of the PPAQ Q8 for
different age groups using specific and age appropriate examples of each PA intensity
category. Creating these new age-specific versions of PPAQ Q8 may help individuals
more accurately report the time they spend in each PA intensity category per day and,
thus, help strengthen the ability of the PPAQ PA assessment battery to accurately
measure and assess habitual PA participation.
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Finally, the results of this STOMP sub-study show the PPAQ Q8 has adequate
concurrent and predictive validity as well as good test-retest reliability among healthy
men and women over 20 yr. Therefore, the PPAQ Q8 can be used, in conjunction with
the other components of the PPAQ, to provide clinicians with a complete representation
of habitual PA participation among healthy men and women across the lifespan.
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Appendix
A. The Paffenbarger Physical Activity Questionnaire
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B. Informed Consent Document for “The Effects of Statins on Muscle Performance”
(STOMP) Study

INFORMED CONSENT FOR PARTICIPATION IN CLINICAL RESEARCH
UNIVERSITY OF CONNECTICUT

PRINCIPAL INVESTIGATOR: Dr. Paul Thompson, M.D., and Linda S. Pescatello,
PhD.
DEPARTMENT: Preventive Cardiology (Hartford Hospital) Kinesiology (Univ of CT)
PHONE: (860) 545- 2899 (Dr. Thompson), (860) 486-0008 (Dr. Pescatello)
EXPECTED DURATION: approximately 6 months
SPONSOR (if applicable): National Institutes of Health (NIH)

I.

You have been asked to participate as a subject in the research study, The Effects
of Statins on Skeletal Muscle Function. The purpose, procedures, and length of
your involvement are stated below:
A. Purpose of research:
Statins (such as Lipitor) are cholesterol-lowering medications that lower
cholesterol levels and also reduce the frequency of heart attacks, cardiac deaths,
and strokes. Unfortunately, statins can cause muscle discomfort or pain called
“myalgia” in patients treated with these drugs. These symptoms often cause
patients who need these medications to stop taking the drug. Therefore, one of
the goals of this study is to document how frequently people complain of muscle
symptoms like aching and cramps. The cause of statin muscle discomfort is not
known, but is often increased by exercise. As a result, this study will also
determine the effect of 80 milligrams of Lipitor on muscular strength and
endurance and aerobic exercise performance in comparison to a placebo (“sugar
pill”).

B. Procedures: Your participation will involve the following procedures:
Prior to the start of the study, a detailed explanation of the study will be
given and you will be interviewed to determine if you meet the
qualifications necessary to participate.
You will have your blood pressure measured up to 3 times at each visit
prior to the start of the study and during V1 and V2 to determine your
eligibility based on your blood pressure. Regarding blood pressure
measurements in the STOMP protocol, if you are on antihypertensive
medication you must have a blood pressure of <140/90 mmHg or you will
not be enrolled and will be referred to your physician. After 3 months, if
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your blood pressure is <140/90, you may be eligible to enroll at that point.
If you have mild hypertension, you will be informed of that during
screening. You will be enrolled and monitored throughout the study. If
your blood pressure remains elevated at the end of the study, you will be
referred to your physician. If your blood pressure is 150/100 or greater, you
will not be enrolled and will be referred to your physician.
If you do not qualify, the doctor or research staff will tell you why. If you do
qualify, you will be asked to read and sign this informed consent prior to your
first visit.
1. On Visit 1, you will report to the Human Performance Lab (Gampel
Pavilion, 2095 Hillside Rd, room 112). You will be asked to complete a
physical activity survey, pain symptom questionnaire, and two psychological
questionnaires. You will then be escorted to our Exercise Physiology
Laboratory for the following strength and exercise assessments:
 The strength of your hands will be measure by asking you to squeeze a
handgrip device. We will measure each hand 3 times to get a good
estimate of your strength.
 The strength of your biceps (upper arm) muscle will be measured using a
Biodex dynamometer. It looks like a universal weight lifting machine.
You will be seated on the machine and a Velcro strap will secure you to
the seat at the hips and across your upper body to prevent extra
movement throughout the testing. Your wrist will be placed snugly
between two padded supports and a wide strap placed across the lower
arm. You will warm up by performing 10 biceps curls at a light
intensity and 10 curls at a moderate intensity. The actual test will
consist of 3 sets of 3 biceps curls with a 5-minute rest between each set.
 The strength of your thigh muscle will also be measured using the Biodex
machine. You will be seated with your arms folded across your chest
and you will be secured by Velcro straps at the thigh, hips, and upper
body to prevent extra movement during the testing. You will warm up
by performing 10 knee extensions (like kicking a ball) at a light
intensity and 10 knee extensions at a moderate intensity. The actual test
will consist of 3 sets of 3 extensions with a 5-minute rest between each
set.

2. On visit 2 you will report to the exercise physiology lab at Hartford Hospital
(85 Jefferson Street, Suite 704) having fasted (no food or beverage other
than water. You will have blood taken from one of your arm veins for
analysis. Blood tests will be performed for liver safety assessments, as well
as cholesterol levels, muscle proteins, and vitamin D. If your TSH (thyroid
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test) or other lab results are outside of the study limits, they will be repeated
to confirm the initial results at another date, prior to performing any
additional study procedures. This will require an additional study visit. Some
of the blood taken during the study will be saved and stored (archived). One
of the tubes of blood drawn will be used for DNA analysis to compare the
variation and patterns in genes in your sample with that in samples from
other people, including subjects with other conditions or diseases. All
information indicating that the sample came from you (such as your name,
birth date and social security number) will be removed. Next, your vital
signs (blood pressure, heart rate, breathing rate), height, weight, and waist
circumference will be measured. You will then undergo a maximal aerobic
test on a treadmill to determine your fitness level. You will wear electrodes
on your chest to monitor your heart rate and the electrical activity
(electrocardiogram-“ECG”) of your heart. You will also breathe through a
snorkel-like mouthpiece, so that your breath can be collected and analyzed
for oxygen and carbon dioxide. During the test you will be asked to exercise
until you cannot go any further.
3. Based on your health history and/or the initial maximal aerobic test results
on visit 2 our staff may require the presence of a medical doctor for your
second and third maximal aerobic tests (visits 3 and 6). If this is the case,
those tests may be scheduled at Hartford Hospital or the Human
Performance Lab at Gampel Pavilion depending on physician and equipment
availability. All other testing will still take place at the Human Performance
lab, as listed below.
4. On visit 3, you will report to the Human Performance Lab in Gampel
Pavilion. You will repeat the muscular strength tests from visit 1 and
perform a knee endurance test on the Biodex machine. For this test you will
perform 30 consecutive maximal knee extensions (like kicking a ball). You
will undergo a maximal exercise test on a treadmill to determine your
aerobic fitness level (note- as mentioned above, this test may be scheduled at
Hartford Hospital, if it than it would be visit 4). This test will be similar to
visit 2 except no electrodes will be attached to your body. You will still
breathe through a snorkel-like mouthpiece, so that your breath can be
collected and analyzed for oxygen and carbon dioxide. During the test you
will be asked to exercise until you cannot go any further. You will be given
a special watch to wear, called an activity monitor. It will monitor your
movements for the next 24 hours. The research coordinator will show you
how to use it.
5. Visit 4 will take place at the Human Performance Lab. You will repeat the
arm and leg strength testing including the knee endurance test on the Biodex
machine. You will be given a cholesterol lowering diet handout and asked
to follow this diet as best possible during the study. At this visit you will
receive your randomly (similar to that of a flip of a coin) assigned study
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medication to take daily at bedtime for 3-months. This is a double-blind
study, which means that neither you nor the doctor will know if you are
assigned to take a placebo (like a “sugar pill”) or 80 milligrams of Lipitor.
The capsules will look identical. Your study drug assignment can be found
out if medically necessary. Please note, if you performed your second
maximal aerobic test at Hartford Hospital, then this would be visit 5.
6. Someone from our research staff will contact you twice per month to
monitor your use of the study drug and to ensure that you have not
experienced any health issues. If you have had any problems that the study
doctor considers clinically significant, you will be asked to return to the
clinic for blood testing within 48 hours. Throughout the study, you will be
instructed to call our 24-hour beeper in case of an emergency.
7.

If at any time you experience muscle discomfort or aching (“myalgia”)
related to the study medication, you may be invited to participate in another
optional part of this study. This additional part of the study requires that Dr.
Thompson or the Preventive Cardiology Fellow, both medical doctors,
perform a needle biopsy on one of your legs. This is done after giving local
anesthesia to the skin and muscle with Novocain. A small incision will be
made in the skin of the upper thigh. A needle, the size of a lead pencil, will
be inserted into the muscle and a small "plug" of tissue (about the size of
three grains of rice) will be removed. The muscle samples will be frozen
and analyzed for gene activity. This type of gene analysis does not reveal
anything significant about your genetic profile or that of your family. This
will be performed at Hartford Hospital.
You may also be invited to participate in this additional part of the study if
you have not had such muscle problems to serve as a “control”, or
comparison subject. Your biopsy sample would be compared to samples
from participants who did experience muscle discomfort. The procedure for
the biopsy is the same as described above. This part of the study is not a
requirement; it is completely voluntary.

8. Visit 5 will take place after 3 months. You will report to the Human
Performance Lab at Gampel Pavilion to have blood drawn for liver and
muscle safety testing. If any of the blood work results are high and the study
doctor considers them clinically significant, you will be asked to return to
the clinic for blood testing within 48 hours. You will bring in any unused
study medication and empty bottles to measure your pill compliance. You
will be given another 3-month supply of the study medication. Please note if
you performed all of your maximal aerobic tests at Hartford Hospital, then
this is visit 6.
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9. Again, someone from our research staff will contact you twice per month
for the remainder of the study to monitor your use of the study drug and to
ensure that you have not experienced any health issues.
10. Visit 6 will take place after 3 months (a total of 6 months after you entered
the study). You will report the Human Performance lab at Gampel Pavilion
having fasted (no food or beverage other than water) for at least 12 hours.
We will measure your vital signs, height, weight, and waist circumference.
You will then have blood taken from one of your arm veins for analysis.
You will complete the physical activity survey and pain symptom
questionnaire. You will then repeat the arm and leg strength testing,
including the knee endurance test. You will repeat the maximal treadmill
exercise test as in visit 3 (please note, as described in item 3 above, if you
performed both maximal aerobic tests at Hartford Hospital, then your third
one must also occur at Hartford Hospital, if so, then this is visit 7 and the
maximal aerobic test would be visit 8). If you are performing your maximal
aerobic test at Hartford Hospital, then vital signs, height, weight, and waist
circumference, as well as the blood draw will occur then, not at the Human
Performance Lab. After the exercise testing, you will wear the activity
watch for 24 hours.
11. Visit 7 is your final visit; it will take place at the Human Performance Lab in
Gampel Pavilion no less than 72 hours after visit 6. You will repeat the arm
and leg strength testing on the Biodex machine, without the knee endurance
test. You will also return the activity monitor. You will bring in any unused
study medication and empty bottles to measure your pill compliance.
Please note- if you completed all three of your maximal aerobic treadmill
tests at Hartford Hospital, your total visits will be 9, as opposed to 7.
12. Altogether, during the study, approximately 4.5 tablespoons of blood (45 ml)
will be taken. This is approximately one fourth the amount taken when
someone “gives blood”.
13. You will be contacted, by phone, 2 weeks after your final visit to monitor
any changes in your health status
14. You may be invited to participate in another optional part of this study. The
purpose of this sub-study is to gather pilot data on statin patients. In this substudy, the cognitive function sub-study, you will be asked to complete a
series of cognitive tests and an MRI scan at the end of the study (while you
are still on the STOMP study drug or placebo) as well as two months after
you have been off of study drug or placebo following study completion. If
you participate in this sub-study, an additional 4 teaspoons of blood will be
drawn at your STOMP Visit 5 and again after you have been off of the study
drug for 2 months. Conducting this study will help us to understand the
chronic effect of statins on cognitive function. Your agreement to participate
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is optional and entirely up to you. You will receive the same treatment and
care under the main study whether or not you decide to participate in the
Cognitive Function Sub-Study. You will be compensated $200 for your
time and effort associated with this study. You will receive the $200 in the
form of a check 6-8 weeks after your last study visit. If you stop your
participation for a medical reason deemed important by the study doctor,
your time will be compensated $50 for each visit that you have completed.
You will not receive compensation for your time and effort if you do not
complete the study for other reasons.

Of the item(s) listed above, the following is/are experimental:
Lipitor is an approved drug and one of the most prescribed medicines in the
whole world. Maximal treadmill tests are done commonly in medicine.
Nevertheless, this entire study is experimental because none of this would be
done to you if you were not participating in the study.

C.

II.

Duration of Participation: This study will take place in both the Human
Performance Lab in Gampel Pavilion at the University of Connecticut and the
Preventive Cardiology Department at Hartford Hospital. Your participation will
last approximately 6 months and you will be asked to participate in a total of 7-9
study visits.
The possible risks, discomforts and side effects of the procedures are described
below, including safeguards to be used for your protection:
1. Atorvastatin is an FDA approved drug for reducing high cholesterol and is in
a class of drugs called “statins.” Atorvastatin is generally well tolerated.
Side effects commonly reported are: Constipation, gas, upset stomach,
abdominal pain, headache, muscle pain, joint pains, rash, loss of strength and
abnormal increases of liver blood tests. If you suffer from any of these
symptoms, or any other symptoms, you should report them to the STOMP
Research Team by contacting Health/Fitness Research lab during normal
business hours at 486-2812. Additionally, you will be given a phone number
that you may call outside of normal business hours if symptoms are severe
and/or intolerable such as severe muscle cramps, flu symptoms, or black or
brown urine. The member of the STOMP research team that receives your
call will record your symptoms and immediately contact Dr. Thompson who
will contact you promptly and advise you.
2. Statins (such as Lipitor) may cause severe muscle problems called
rhabdomyolysis, which is a breakdown of muscle leading to muscle pain,
kidney failure requiring dialysis and even death. This problem happens once
in every 10 million prescriptions. This risk may be increased by exercise,
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but this should not happen in this study because of the close medical
attention you will receive.
3. Statins can also cause abnormalities in tests of liver function. This is really a
measurement, and not a medical problem, that usually goes away without
stopping the medicine, and almost never leads to a long-term problem.
4. Other side effects that are not known at this time could occur during your
treatment. This could include allergic reaction. A severe allergic reaction
can be life threatening. You will be informed of any changes in the way the
trial is done and of any newly identified risks to which you may be exposed.
You will be informed in a timely manner if other information becomes
available that may be relevant to your willingness to continue your
participation in this trial.
5. Exercise and exercise testing can cause a heart attack and even sudden death.
This happens once in 10,000 tests in people with heart disease and much,
much less in healthy people. The research staff will observe you closely
during the exercise testing sessions to minimize the possibility of injury and
a clear explanation of all procedures and equipment will be given to you.
6. You will almost certainly become sore and tired and possibly weak from the
exercise sessions. These feelings should go away in 5-6 days. If you do not
perform strenuous exercise for 3 days following the exercise, the tiredness
will go away faster. If the symptoms do not go away after 7 days or if you
experience black or brown urine, contact Dr. Pescatello’s team immediately
with the cell phone number provided to you. The team member who takes
your call will contact Dr. Thompson who will promptly contact you to
advise you.
7. The risk of serious injury (such as a muscle pull or strain) is very small, but
can happen.
8. During the collection of blood samples you will feel pain where the needle is
inserted and you may have bruising at the puncture site. There is also the
risk of infection, but this is very rare. Dizziness and/or fainting sometimes
occur during or shortly after blood is drawn. A person trained in taking
blood will draw your blood sample to minimize these risks.
9. Fasting (nothing to eat or drink except water) for 12 hours before each visit
could cause dizziness, headache, stomach discomfort and rarely fainting.
10. There are no known side effects associated with ECGs, other than possible
skin irritation where the ECG patch was applied.
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III.

You may get no personal benefits out of participating in this study although:
1. Study medication may lower your LDL (bad cholesterol) level.
2. You may contribute to our knowledge of how Lipitor and exercise affect
muscle.

IV. This is a study and not a treatment for a condition that you may have. Consequently,
you are only deciding whether or not to participate in how the cholesterol drug called
Lipitor along with exercise affect muscle. If you want to find a treatment for any health
problem, you should discuss this with Dr. Thompson or your own doctor and not
volunteer for this study.
V. Dr. Thompson, Dr. Pescatello and their staff are willing to answer any questions
you may have concerning the procedures herein described. You should not sign this
consent until all of your questions about the study have been answered. If you have
questions about the research in general, you can call the University of Connecticut
Institutional Review Board at (860) 486-8802, or Dr. Laurine Bow, Vice President
for Research at Hartford Hospital, at (860) 545-2893.
If you have questions about the treatments during the research project or if you have
a research-related injury or emergency, you should call Dr. Paul Thompson, M.D. at
(860) 545-2899.
If you have questions about your rights as a research subject you may call the
University of Connecticut Institutional Review Board at (860) 486-8802 or the
Institutional Review Board at Hartford Hospital at (860) 545-2893 and speak to an
IRB representative.
If you have any confidential issues to discuss, such as problems or complaints, you
may call Patients Relations at Hartford Hospital (860) 545-1400 and talk to
someone who is not connected with the research.

VI. Your participation is voluntary and you may refuse to participate and/or withdraw
your consent and discontinue participation in the project at any time without penalty
or loss of benefits to which you are otherwise entitled. Your decision whether or not
to participate will not affect your future medical care at the Cholesterol
Management Center or any other program at Hartford Hospital. Your decision will
also not affect how Dr. Pescatello or her staff feels about you since they realize that
participation in such projects is totally voluntary.

VII. You will be reimbursed up to $720 for your time and effort at the end of the study.
You will receive your payment in the form of a check within 6-8 weeks of
completing the study. This will be reported to the Internal Revenue Service as
income received. If you stop your participation for a medical reason deemed
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important by Dr. Thompson your time will be compensated in full. You will not be
reimbursed for your time and effort if you do not complete the protocol for other
reasons.
VIII. Your confidentiality will be guarded to the extent possible. Your records
will be maintained in accordance with applicable state and federal laws.
However, private identifiable information about you may be used or
disclosed for purposes of this research project. You may request that your
records be released to your own doctor. Your blood samples will be stored
in small tubes labeled only with an identification number. Therefore, your
identity will never be revealed to anyone or be connected with genetic
information from your samples. They will be stored in a locked freezer until
all study testing has been completed. Only Dr. Thompson and members of
his research staff will have access to this freezer.
The cells, blood, or other specimens resulting from this study may be valuable for
scientific research. May the University of Connecticut, and collaborating sites
Hartford Hospital, and University of Massachusetts Amherst retain your specimens
after the end of this research project with identifying information for use in future
research?
_____ YES
information.
_____ NO

my samples may be saved for future research without identifying

my samples must be destroyed at the end of this research project.

The information that may be used or disclosed as part of the research includes
the following:
1. Your study records
This information may be used or disclosed by:
1. Dr. Thompson and researchers working under his supervision.
The information may be disclosed to:
1. The Hartford Hospital Department of Research Administration
2. The Hartford Hospital Institutional Review Board
3. The University Human Subjects Review Committee of the University of
Massachusetts
4. Researchers working under the direction of Dr. Hoffman at Children’s
National Medical Center.
5. Researchers working under the direction of Dr. Benjamin Levine and Dr.
Ronald Haller at the University of Texas Southwest Medical Center.
6. The U.S. Food and Drug Administration
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7. The Data Safety Monitoring Board
The purpose(s) of the use or disclosure of this information is (are):
1. To answer the research questions
2. To ensure the study is being conducted properly and that your rights as a
participant are protected.
The use or disclosure of the information is permitted until completion of the study
and analysis and publishing of the results.
By signing this consent you are agreeing to the use or disclosure of your protected
health information as described above. If you do not agree to the use or disclosure
of the information as described and therefore do not sign this consent, you cannot
be in the study.
If, after signing the consent, you change your mind, you have the right to revoke
your consent, in writing. However, you may be withdrawn from the study.
Once private information is disclosed, it is subject to redisclosure by the recipient,
and no longer can be considered protected.
You may obtain a copy of the Hartford Hospital Privacy Notice for a complete
description of the Hospital’s privacy practices for protected health information.
You have the right to review the Notice before signing this consent.
The results of this research trial may be presented at meetings or in publications;
however, your identity will not be disclosed in these presentations.

IX.

In case of any injuries as a direct result of taking part in this research project, you
will receive help in the following way:
If you have medical insurance, the hospital will collect fees for medical treatment
from your insurance company. If you are not fully covered or are uninsured,
Hartford Hospital will cover these expenses. The hospital will not pay medical
expenses at other hospitals or pay for pain and suffering, travel, lost wages, or other
indirect costs of taking part in this project.
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X.

Signatures

I have been given a copy of this informed consent form to keep. I have read it, and I
hereby voluntarily agree to participate in the research study, The Effects of Statins on
Skeletal Muscle Function, and consent to the performance of the above procedures upon
me.
________________________________________________________________________
Participant's Signature // Date

Legally authorized healthcare representative // Date
_____________________________________________________
Person Obtaining Consent // Date

___________________

Witness (person observing the explanation of the above information to the participant) optional unless consent is presented orally.
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C. Paffenbarger Physical Activity Questionnaire Data Entry Protocol
Before entering the data from the questionnaire first walk through each question to be
sure everything has been entered.
Fill in any blanks. Use the guidelines below to aid you in filling in the most accurate
response. “Protocol” refers to this document.
Question

Possible solution

Question #1

Post questionnaire

Question #2

Question #7, post questionnaire

Question #3

Post questionnaire

Question #4 (see data entry log below for more)

Question #6-8, protocol

Question #5

Post questionnaire

Question #6

Post questionnaire

Question #7

Question #6, 8, post questionnaire

Question #8 (see data entry log below)

Question #1-7, post questionnaire, protocol

Any changes that need to be made should be written on the original questionnaire. Do
not cross out or erase any existing data. Just note what was entered on the database, an
explanation for the change, your initials, and the date. This information will also go on
the data entry log sheet. See examples listed under “Examples of problems encountered
when examining questionnaires” at the end of this document.
Data entry site:
Enter the link below into your web browser; it will take you to the data entry page.
http://10.239.3.35:95/login.aspx
The data entry page mimics the actual Paffenbarger Physical Activity Questionnaire. So
each item on the Questionnaire has a corresponding box to enter to on the web data entry
page.
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Additional data entry guidelines:
All subject ID’s should be entered in the following format:
Site location (UC, UM, or HH) followed by a dash “-“ then the number. For example
UC-312. Do not leave out the dash. Note there are no spaces between the dash and the
location or number.
For question #1
If nothing is entered or a note is written by the subject akin to “walk to and from
class 3d/wk the default will be 12 blocks.
For question #3
If the amount of flights/day is greater than 40, we will assume the subject
misunderstood the question and answered in steps, as 10 steps is equal to 1 flight.
We will correct it by dividing the answer by 10, so 50 flights would be 5 flights.
If the question is left blank, the default will be 1 flight.
For question #4:
The drop down list may not contain all activities that are written on the
questionnaire. Many of the common “missing” activities are listed in table 1, use the
substitutions listed when encountering them on a questionnaire. Substitutions for
activities not listed should be brought to the lab meetings for discussion.
Activities that appear on the web entry for #4 with light, moderate, vigorous options
but where the questionnaire does not specify refer to question #7 and use the
following guidelines to determine which intensity to enter.
<3 – Light
3-5 – Moderate
5> - vigorous
If a questionnaire lists amount of times per year, or how long as a range, for instance
35-40x per yr or 35-45 minutes, then enter the average, so 37.5x/yr and 40 minutes
for those two examples.
For activities listed that have an options such as low impact or hi-impact aerobics
and no indication is given as to which it is then split the times per year and enter both
activities. See example 4 below.
For question #7
If the subject marks the RPE chart in between 2 numbers, rather than circling the
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most appropriate number then:
If the preceding number is odd, round up, if it is even, round down. For example if
the questionnaire indicates intensity between 3 and 4, you would enter 4 on the
database.
If the question is left blank, look at question 6, if the subject answered “yes” to
engaging in activity long enough to break a sweat, get your heart thumping, or get
out of breath, then we will consider the effort to be vigorous, circle 6. If they
answered no, then use question 2 to estimate an answer.
If Question 2=
a
b
c
d

then …
Choose 0.5
Choose 2
Choose 3
Choose 5
for question 7.

For question #8
Both columns, weekday and weekend day should each add up to 24 hours. If they
do not, examine questions #1, 2, 3, 4, 5, 6 to find out how active this person is, for
instance, how many blocks, flights do they cover/day (#1-2), what activities do they
do and how often (#4). Do they think they get enough exercise, what activities they
do daily that gets their heart pumping, and brings on a sweat (#6). Use these to make
your best judgment on where to add or subtract hours (depending if the total was < or
> 24).
To be most consistent, we can generally assume, if the columns total is <24, the extra
hours should be added to light, or sitting. This is the most likely activity that goes
unnoticed by the individual. The only time extra hours should go into moderate, or
even vigorous is if:
1) Vigorous and/or moderate hours are blank AND the individual indicates
regular participation in sports on questions 4 and 6.
2) The amounts entered in vigorous and/or moderate are less than what is
indicated in question 4.
For example, subject X indicates in question 4 that they play soccer 150 times
per year for 2 hours each bout, and run 200 times per year, 45 minutes each
bout. In question 8, vigorous hours during the week are blank, and weekend is
1. According to question 4, 150 times per year is roughly 3 days per week, and
running 200 times per year is nearly 4 times per week. So, on average they are
spending 9 hours per week (2 hr x 3 + 45min x 4) in moderately vigorous
activity. In this case, enter 1 hour in the vigorous weekday column. The
running however, may or may not be vigorous per se but because the PPAQ
MET ranges from 4 to 10, we can justify adding another hour to the vigorous
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weekend column, thus the total per week, on average would be 9.
Most importantly, make sure to fill out the data entry log for each subject entry, any
judgment you make on questions #4 or #8 must be written into the notes section, as well
as any notes written on the hard copy. Anytime a change or clarification is made on the
original hard copy, circle the change, so it is clear what to enter into the database. For
example, if a subject writes 8-10 blocks per day for question #1, you should cross it out
with a single line and write 9, with a circle around it. See example 3 below.
Examples of problems encountered when examining questionnaires
Example 1:
Subject XX enters an 8 on question #7 (when you exercise, how hard do you
work, circle on following scale). Yet, the subject listed no activities or exercise
in question 4 or 6 and listed zero hours per week doing vigorous activity for
question 8.
It is likely that the subject did not fully understand the question. If this subject spends
little or no time doing vigorous activity and did not list any exercise in #4 or #6 it is
likely they are sedentary and do not exercise or exert themselves very much. In this case
a 3 for #7 would be more appropriate. Circle a 3 and then write a brief note such as:
Subject listed 8 (vigorous) but did not list any exercise #4, #6, or time spent
performing vigorous activity in #8, so I entered a 3 in the database, MK 6/26/07.
*note this info will also be written on the data entry log sheet.
Example #2:
Subject XY lists “running” 2-3 time per week for question #6, yet nothing is
listed in question #4. Since this activity is something the subject performs
regularly it should be listed in #4, so we must figure out the name, intensity,
number of times/yr, and hours/minutes performed. For type of activity, we list
running. Times per year would be 130 (2.5 times/wk x 52 wk/yr). For intensity
we can examine question #7. The subject circled a 6 (according to our protocol
this is vigorous). Estimates of hours and/or minutes performed should come
from question #8. Note how many hours/wk is spent doing vigorous exercise. In
this case the person listed 1 hour/day during the week and .5/day on the
weekends. It is likely, since no other activities are listed anywhere on the
questionnaire that time listed in the vigorous category primarily pertains to the
subject’s running. Though the subject indicated 2-3x per week in #6, 30-60
minutes daily is too much, (there are some other activities, perhaps done
intermittently that were not borne out on the questionnaire); since the
questionnaire is a general indication, we must estimate. We will not concern
ourselves with the extra vigorous activity on the days the subject does not run.
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In this case on days the subject runs it is for 30 or 60 minutes of vigorous
exercise, so 45 minutes is a fair estimate to put for time in #4. Leave “years
participation” blank.

The entry for #4 should read:
number of
times/ year

Sport, recreation, or other physical activity
participation
a. Running (vigorous)

hours

130

minutes

45

The notation you write on the questionnaire should resemble the following:
Question 4 was blank but question six listed running as a regular activity. I
listed running from #6, vigorous intensity from number #7, 130 times/yr from #6
(2-3/wk x 52 wk/yr), and 45 minutes from #8 (subject indicated 30-60 min
vigorous activity/day), MK 6/26/07
This case is an example, it would have been more difficult to predict if the hours listed
for vigorous exercise was considerably higher (for instance 3-4 hours/day) or if question
#7 was also entered incorrectly (in this case see example 1 above). In such cases, follow
the protocol as best as you can, make your best estimate; note the change and how/why
you did it. In the case where the hours/min for cardio exercise cannot be estimated with
reasonable accuracy (walking, running, biking, swimming< etc), enter 30 minutes as a
default.
Example #3:
Question 8 was not correctly filled out, as both weekday and weekend hours did
not total 24. See below.
Usual weekday hrs/day

Usual weekend hrs/day

a. Vigorous

3-4

1

b. Moderate

2-3

1

c. Light

5

2

d. Sitting

5

2

e. Sleeping or reclining

8

8
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Total

23-27

14

In this case, we can take the middle values for the range of the Vigorous and
Moderate during the week numbers. This way the total adds to 24. The subject
indicates considerably less Vigorous and Moderate activity on the weekend than
during the week, as both are 1 hour, compared to 3.5 and 2.5. Since sleeping is 8
hours for both weekday and weekend, we will assume the subject purposely sleeps
8 hours a day regardless if it is a weekend or not. So we can assume that the
extra 10 hours needed to make the weekend column total 24 can be put into light
and sitting activity. In both columns the subject put the same values for light and
sitting activity, so we can assume that they spend the same amount of time doing
both, so the remaining 10 can be split equally between the two (5 and 5). See
below. Note the notation.
Usual weekday hrs/day

Usual weekend hrs/day

a. Vigorous

3-4

3.5

1

b. Moderate

2-3

2.5

1

c. Light

5

2

7

d. Sitting

5

2

7

e. Sleeping or reclining

8

8

Total

24

24

Note that in spite of the examples given, there will inevitably be some instance where it is
not clear how to proceed. These instances can always be brought to the attention of the
lab group for discussion.
Example 4:
Subject XY enters aerobics as the lone activity for question #4, 300 times/year,
for 35 minutes. The options in the web drop down menu are hi- or low-impact.
There is no indication in question #4, 5, or 6 as to which type of aerobics was
performed. Check question 7, if they indicate a degree of exertion 5 or greater,
we will assume hi-impact aerobics, if degree of exertion is lower than 5, assume
low impact. In the rare case that question 7 is not clear, we should split this
into two entries, one for low- and one for hi-impact aerobics, each for 150
times/yr for 35 minutes.
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Addendum
Note, as of 8/9/07, any notation to changes made in any questionnaire, that are covered in
the protocol can be written as:
Q#(1-8) adjusted according to protocol. (your initials) (date you entered it).
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Table 1
Paffenbarger PA data entry substitutions on question #4 for activities not listed
Activity from questionnaire

Substitution to enter into database

Running (with no intensity listed)

See Q #7, anything <3 use running/jogging
3-5 use 8 min/mile, >5 use <7 min/mile

Running – light

running/jogging

Running – moderate

running 8 min/mile

Running - hard/heavy/vigorous

running <7 min/mile

Biking/cycling (with no intensity listed)

See Q#7, follow protocol for question #4

Billiards/pool

Croquet (2.5 METS)

Snowboarding

Downhill skiing

Rollerblading

Roller-skating

Team sport not listed (ultimate Frisbee, European team handball)

Soccer

Cardio

Health Club

Cheerleading

Gymnastics

Motorcycle racing (not riding but off road/dirt track racing)
Paintball

Horseback riding
Soccer

Tae Bo

Hi-impact aerobics

Dance Dance Revolution (DDR)

Hi impact aerobics

Elliptical training

Bicycling moderate (8 METS)

Skiing

Downhill Skiing

Workout at gym

Health club

Marching band (1 fall season = 48 times/yr, 3 hours)

Walking

Dodgeball

racquetball

Colorguard

dancing

Spinning

vigorous or moderate bicycling

Broomball

hockey

Step aerobics

low-impact aerobics
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Kickball

Baseball

Any sport, intramurals

Soccer

Hurling

Lacrosse

Camogie
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